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Abstract:Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting
solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field
and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized ap-
proach to CMVmanagement. An international multidisciplinary panel of experts was convened to expand and revise evidence and
expert opinion-based consensus guidelines onCMVmanagement including prevention, treatment, diagnostics, immunology, drug
resistance, and pediatric issues. Highlights include advances in molecular and immunologic diagnostics, improved understanding
of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immuno-
suppressive agents, and more savvy approaches to treatment resistant/refractory disease. The following report summarizes the
updated recommendations.
(Transplantation 2018;102: 900–931)
The past 5 years has seen exciting advances related to theunderstanding, diagnosis, and treatment of Cytomega-
lovirus (CMV). We currently stand on the cusp of moderniz-
ing the management of CMV infection posttransplant.
Despite these advances, CMV remains one of the most com-
mon complications affecting solid organ transplant recipients
(SOTR), still befitting the designation: “a transplantation
troll.”1 In addition to the direct effects of CMV infection
and disease, there are “indirect effects,” both general and
transplant-specific, and higher rates of all types of infection,
graft loss, morbidity, and mortality.2,3 A panel of experts on
CMVand solid organ transplantation (SOT) was previously
convened in 2008 and 2012 by The Infectious Diseases Sec-
tion of The Transplantation Society to develop consensus
guidelines on CMV management, subsequently published
in 20104 and 2013.5 Topics included diagnostics, immunol-
ogy, prevention, treatment, resistance, and pediatrics. Given
numerous recent advances in the field, a third meeting of ex-
perts was convened inMarch 2017 to update these guidelines.
The expert panel rated the quality of evidence on which
recommendations are based by following a process used in
the development of other guidelines, including those by the
Infectious Diseases Society of America. The Grading of Rec-
ommendations Assessment, Development and Evaluation
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system allows for a systematic weighting of the strength of
recommendation (eg, “high, moderate, low, very low”) and
quality of evidence (eg, “strong, weak”) (Table 1).6-10,13
We used the following definitions, consistent with the
American Society of Transplantation and the CMVDrug Devel-
opment Forum recommendations for use in clinical trials14,15:
• CMV infection: evidence of CMV replication regardless of
symptoms (differs from latent CMV); “defined as virus isola-
tion or detection of viral proteins (antigens) or nucleic acid
in any body fluid or tissue specimen”15
• CMV disease: evidence of CMV infection with attributable
symptoms. CMV disease can be further categorized as a viral
syndrome (ie, fever, malaise, leukopenia, and/or thrombocy-
topenia), or as tissue invasive (“end organ”) disease.
As in our prior versions, the term deoxyribonucleic acid
in blood (DNAemia) will be used instead of viremia, to re-
flect the detection of CMVDNA in blood or plasma (whether
actively replicating virus or not). For accuracy, the phrases
“viral load” or “quantitative nucleic acid amplification
testing (QNAT)” are used instead of “polymerase chain
reaction (PCR).”
DIAGNOSTICS
Pretransplant Testing
Given that the CMV serostatus of donor and recipient
(D/R) are key predictors of the risk of CMVafter transplant
and guide decisions on antiviral prophylaxis or preemptive
TABLE 1.
GRADE strength of recommendations and quality of the evidence6-12
Strength of recommendation
and quality of evidence
Clarity of balance between desirable
and undesirable effects
Methodological quality of supporting
evidence (examples) Implications
Strong recommendation,
high-quality evidence
Desirable effects clearly outweigh
undesirable effects, or vice versa
Consistent evidence from well-performed
RCTs or exceptionally strong evidence
from unbiased observational studies
Recommendation can apply to most patients
in most circumstances. Further research is
unlikely to change our confidence in the
estimate of effect
Strong recommendation,
moderate-quality
evidence
Desirable effects clearly outweigh
undesirable effects, or vice versa
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect,
or imprecise) or exceptionally strong
evidence from unbiased
observational studies
Recommendation can apply to most patients
in most circumstances. Further research
(if performed) is likely to have an important
impact on our confidence in the estimate
of effect and may change the estimate.
Strong recommendation,
low-quality evidence
Desirable effects clearly outweigh
undesirable effects, or vice versa
Evidence for at least 1 critical outcome
from observational studies, RCTs with
serious flaws or indirect evidence
Recommendation may change when
higher-quality evidence becomes available.
Further research (if performed) is likely to
have an important impact on our confidence
in the estimate of effect and is likely to
change the estimate
Strong recommendation
very-low-quality evidence
(very rarely applicable)
Desirable effects clearly outweigh
undesirable effects, or vice versa
Evidence for at least 1 critical outcome
from unsystematic clinical observations
or very indirect evidence
Recommendation may change when
higher-quality evidence becomes available;
any estimate of effect for at least 1 critical
outcome is very uncertain.
Weak recommendation,
high-quality evidence
Desirable effects closely balanced
with undesirable effects
Consistent evidence from well-performed
RCTs or exceptionally strong evidence
from unbiased observational studies
The best action may differ depending on
circumstances or patients or societal values.
Further research is unlikely to change our
confidence in the estimate of effect.
Weak recommendation,
moderate-quality
evidence
Desirable effects closely balanced
with undesirable effects
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies
Alternative approaches likely to be better for
some patients under some circumstances.
Further research (if performed) is likely to
have an important impact on our confidence
in the estimate of effect and may change
the estimate
Weak recommendation,
low-quality evidence
Uncertainty in the estimates of
Desirable effects, harms, and burden;
Desirable effects, harms, and burden
may be closely balanced
Evidence for at least 1 critical outcome
from observational studies, from RCTs
with serious flaws or indirect evidence
Other alternatives may be equally reasonable.
Further research is very likely to have an
important impact on our confidence in the
estimate of effect and is likely to change
the estimate.
Weak recommendation very
low-quality evidence
Major uncertainty in the estimates of
desirable effects, harms, and burden;
Desirable effects may or may not be
balanced with undesirable effects
may be closely balanced
Evidence for at least 1 critical outcome
from unsystematic clinical observations
or very indirect evidence
Other alternatives may be equally reasonable.
Any estimate of effect, for at least 1 critical
outcome, is very uncertain.
GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trials.
© 2018 Wolters Kluwer Kotton et al 901
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
treatment, serologic tests with high sensitivity and high spec-
ificity are recommended. A test measuring CMV-specific IgG
should be used, as serologic tests measuring IgM or IgG and
IgM combined have poorer specificity and may cause false-
positive results. Neither of the latter 2 should be used for
screening.16-18 Not all serologic tests are equivalent, and per-
formance characteristics of the specific test used should be
understood.19 Discordant CMV IgG serology results have
been reported for 1.0% to 2.6% of samples tested by com-
monly used assays.16,17 A change of the serologic assay re-
quires evaluation of its performance, including comparison
with the previously used assay.
If the donor or recipient is seronegative during the pre-
transplant evaluation, serology should be repeated at the
time of the transplantation. Interpretation of serology results
can be difficult in donors and recipients with recent transfu-
sion of IVIG and other blood products (platelets, plasma,
red blood cells), given the potential for passive transfer of an-
tibody,20 and a pretransfusion sample should be tested when
possible. In seropositive children younger than 12 months,
passive transfer of antibody can lead to transient false-
positive serologic results.20 Cell-mediated immunity (CMI)
assaysmay be useful in assisting in establishing true immuno-
logic status in individuals who may have passive anti-
body.21,22 Testing for CMV-specific CMI appears to be less
useful in deceased donors because of a high prevalence of in-
determinate results.23 In infants younger than 12 months,
nucleic acid amplification tests (NAT) of urine or oral sam-
ples may be helpful to identify infected patients, as children
with postnatal primary infection appear to persistently shed
virus for long periods,24 whereas a negative CMV NAT can-
not exclude past exposure. Thus, if equivocal serologic assay
results are obtained in the donor or in the recipient, we rec-
ommend assigning the highest appropriate CMV risk group
for posttransplantation management decisions.
Posttransplant Testing
Serology has no role in the diagnosis of active CMV repli-
cation and disease posttransplantation. Serologymay be used
to determine ongoing susceptibility to community-acquired
disease in patients seronegative before transplantation who
do not develop infection or disease after transplantation.
Using CMV-antibody binding assays, seroconversion at
the end of antiviral prophylaxis was not a useful predictor
of future CMV disease in CMV-mismatched patients,25,26 al-
though seroconversion at 6months after transplant in D+/R−
patients given 100 days of antiviral therapy (ie, 3 months af-
ter the end of prophylaxis) conveyed a reduced risk for late
CMV disease.26 In a pilot study in CMV-mismatched pa-
tients managed using preemptive therapy, measurement of
antibodies neutralizing epithelial cell infection, particularly
when combinedwithCMI studies was identified as a possible
predictor of future CMV disease risk.27
Viral culture of blood for detecting CMV has limited clin-
ical utility due to poor sensitivity for diagnosis of disease.
Conversely, there is no role for CMV culture of urine or
oral secretions due to poor specificity for CMV disease (ver-
sus viral shedding).28 Quantitative nucleic acid amplification
testing in blood is the cornerstone for diagnosis andmonitor-
ing for CMV infection and disease; QNAT is preferred over
antigenemia because of standardization and other technical
reasons, as previously described.5
Quantitative nucleic acid amplification testing is the pre-
ferred method for diagnosis of CMV infection, guiding pre-
emptive strategies, and monitoring response to therapy.29-35
There are numerous commercial reagents and automated
platforms available for quantitative CMV DNA testing, as
well as increasing data on the performance characteristics
of these tests. Plasma and whole-blood specimens both pro-
vide prognostic and diagnostic information regarding CMV
disease.36-40 CMV DNA is generally detected earlier and
in greater quantitative amounts per unit volume (ie, mL) in
whole blood compared with plasma. Persistent plasma
DNAemia has been shown to be a better predictor of relapse
at day 21 of treatment comparedwith persistentwhole-blood
DNAemia.38 There is evidence that CMV DNA exists pre-
dominantly as small fragments in plasma,41 this may not to
be true to the same extent for whole blood as both intracellu-
lar and extracellular DNA are detected.Morework is needed
to understand the form of DNA in whole blood samples;
paired sample studies are required to establish correlation
of results between the 2 sample types. Thus, when serially
monitoring patients, 1 specimen type should be used.
Calibration of tests with the World Health Organization
(WHO) international standard42 has led to improved agree-
ment of viral load values,43 therefore all results should be re-
ported as IU/mL. Important differences still exist due to
a variety of factors44-46 including extraction method, am-
plification target, probe, nonstandardized quantification of
secondary standards45,47,48 and amplicon size.41 After cali-
bration, commutability needs to be demonstrated, meaning
that patient samples and calibrators behave similarly in a
given quantitative test. Commutability of current assays cal-
ibrated to the WHO international standard varies widely.49
The increased use of commercial assays that address these
factors should decrease variability; a recent study showed
good reproducibility in viral load values across multiple lab-
oratories when using a commercial test calibrated to the
WHO standard.50 Such agreement allows comparison of
data across different transplant centers using the same test.
The QNAT results should be demonstrated to be linear in
the clinically important range between the lower and upper
limits of quantification (LLOQ, ULOQ). The LLOQ varies
amongst assays with newer, highly sensitive assays demon-
strating LLOQ less than 200 IU/mL. Assays results reported
as detectable below the LLOQ represent very low levels of
CMV DNA that may not be clinically significant. The preci-
sion of QNAT results is such that changes in values should be
at least threefold (0.5 log10 IU/mL) to represent biologically
important changes in viral replication.50-53 The QNAT vari-
ability is greatest for viral loads of 1000 IU/mL (3 log10)
and below, where changes may need to be greater than five-
fold (0.7 log10 IU/mL) to be considered significant. Reporting
results as both integers and log10-transformed data may help
clinicians avoid overinterpreting small changes in viral load.
It remains imperative that laboratories use quantitative ex-
ternal standard materials (independent of that provided by
the manufacturer) to monitor quantification across different
lots of reagents to ensure consistency in assay performance.
Quantitative nucleic acid amplification testings should accu-
rately quantify the common CMV genotypes. If the labora-
tory changes QNAT or extraction methods, a comparison
must be performed documenting the performance character-
istics of the new versus old tests. Until QNATs have been
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better harmonized, a single test should be used for clinical tri-
als and for monitoring patients over time. Given the rapid
replication dynamics, CMVQNAT results should be available
within 24 to 48 hours for optimal clinical decision making.
Consensus viral load thresholds to initiate preemptive ther-
apy need to be defined, but widespread use of laboratory-
developed tests and paucity of assays calibrated to the
WHO International Standard has limited the ability to per-
form such studies. Moreover, the D/R risk group and expo-
sure to lymphocyte-depleting antibodies need to be taken
into account. Early work has shown that higher viral load
values correlate with increased risk for disease30,31 (see Pre-
vention section for further discussion). It is important to note
that these recent studies were done with different laboratory
developed assays, specimen types (plasma, whole blood), and
patient populations, so these thresholds cannot simply be
adapted. This leaves individual centers with the task of deter-
mining appropriate thresholds in their patient populations,
and emphasizes the urgent need to perform collaborative
studies to determine consensus threshold in IU/mL, which
should be increasingly practical with the availability of
commercial assays.
The viral load kinetics (rapid doubling time) in high-risk
groups suggests that the frequency of viral load testing will
impact the effectiveness of a preemptive strategy (ie, more fre-
quent testing will be more effective). The half-life of viral
loads is such that monitoring patients on therapy should be
done at least weekly.32 Dynamics of CMV loads over time
may be more important in predicting disease than any abso-
lute viral load value,30 especially when close to the LLOQ.
However, the LLOQ varies among the different viral load
tests; an LLOQ of greater than 1000 IU/mL (using either
whole blood or plasma) may be too insensitive and hence
inadequate for preemptive strategies aiming at antiviral treat-
ment before disease.54 Conversely, a very sensitive test (LLOQ
<10 IU/mL)may detect latent virus particularly if whole-blood
specimens are used, which limits the clinical utility of an ex-
tremely sensitive test.
Whenmonitoring a response to treatment, there is concern
that highly sensitive tests may increase the time to reach an
undetectable viral load, thus unnecessarily exposing patients
to prolonged periods of antiviral therapy. A recent study
showed that using a more sensitive test does increase the time
to reach an undetectable viral load; however, there was a
trend towards shorter duration of therapy with the more sen-
sitive assay.55 Finally, treatment until viral load values are less
than 137 IU/mL is predictive of a clinical response.56 Though
there is value to using highly sensitive assays, the practice of
continuing therapy until successive viral load tests are unde-
tectable may not be necessary when using such tests (ie, with
highly sensitive assays, multiple very low results might be suf-
ficient before stopping therapy).
Diagnostics for Tissue-invasive Disease
The definitive diagnosis of tissue-invasive disease relies on
detection of CMV in the tissue specimen. Identification
of CMV cytopathic changes or CMV antigens by immuno-
histochemistry15,57,58 represents the gold standard for the di-
agnosis of tissue-invasive disease. Not all antibodies and
staining procedures have equal sensitivity and the perfor-
mance may differ between fresh and formalin-fixed, paraffin-
embedded tissue.59
Gastrointestinal disease in all organ transplants and pneu-
monitis in lung transplant recipients may have undetectable
or low DNAemia.60,61 Plasma QNAT has a high sensitivity
for diagnosis of gastrointestinal disease in D+/R− patients,
which decreases substantially in R+ patients.62,63
Viral culture of tissue samples, though not available in
most laboratories today, may improve sensitivity compared
to histopathology eg, in gastrointestinal disease.63 However,
in patients with viremia the specificity of culture results of tis-
sue for end-organ CMV disease may be limited. Similar con-
siderations apply to the more sensitive molecular testing.
Some studies have shown positive QNAT tissue results in
cases with a clinical suspicion of gastrointestinal CMV dis-
ease, however, in which histopathology and DNAemia were
negative.64,65 Tissue QNAT may be preferable to qualitative
NAT due to higher specificity, but studies are needed to de-
fine thresholds and to provide a standardized approach for
QNAT in tissue-invasive CMV disease.
In lung transplant recipients, the detection of the CMV
by QNAT in bronchoalveolar lavage (BAL) reflects CMV
replication in the lung rather than contamination with
oropharygeal fluids.66 Qualitative NAT detecting CMV-DNA
in BAL specimens in lung and nonlung transplant recipients
may not be specific for a diagnosis of CMV pneumonitis.67,68
Quantitative NAT is preferred on BAL specimens and increased
DNA levels may better correlate with symptomatic CMV
disease.61,69–71 Further work is needed to standardize QNAT
on BAL samples including development of thresholds using
normalized reporting units.69,72
Central nervous system disease in SOTRs is extremely
rare. In the absence of further clinical studies, the presence
of CMV DNA in the cerebrospinal fluid likely represents
CMV disease necessitating treatment.
The diagnosis of retinitis is based on ophthalmologic ex-
amination; CMV DNAemia is rarely useful as a predictor
of CMV retinitis, although it may be positive before and at
the time of diagnosis. A positive QNAT in vitreous fluid
may be helpful in guiding the diagnosis of retinitis.
Consensus Statements and Recommendations
• The availability of the WHO-approved CMV international
standard has led to improved agreement of plasma viral load
values between various assays.43 Differences still exist due to
a variety of factors,44-46 including matrix, extraction method,
amplification target, amplicon size, hybridization/detection
probe, nonstandardized quantification of secondary stan-
dards,45,47,48 and use of noncommutable standards.
• Global harmonization and development of universal thresh-
olds will be facilitated by using assays where all steps are
highly standardized. The increased availability of appropri-
ately designed, affordable commercial assays should acceler-
ate these processes.
• We recommend performing donor and recipient CMV IgG se-
rology pretransplantation for risk stratification (strong, high).
• We do not recommend IgM testing (strong, low).
• We recommend repeat serologic testing at the time of trans-
plant if pretransplantation serology is negative (strong, low).
• We recommend that in adults, an equivocal serologic assay re-
sult in the donor be assumed to be positive, whereas in the re-
cipient this result be interpreted to assign the recipient to the
highest appropriate CMV risk group for posttransplantation
management decisions (strong, low) (for guidance on infants
and children younger than 12 months, see Pediatrics section).
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• We do not recommend viral culture of blood, urine, or oral se-
cretions for the diagnosis of active CMV infection or disease
(strong, high). Positive cultures of BAL samples may not al-
ways correlate with disease.
• We do not recommendQNATon urine and oral secretions for
surveillance or diagnosis of CMV disease (strong, low).
• We recommend usingQNATcalibrated to theWHO standard
for diagnosis, surveillance to guide preemptive antiviral treat-
ment, and for therapeutic monitoring due to the ability to har-
monize and standardize these tests (strong, high). Resultsmust
be reported as IU/mL and termed as DNAemia rather than vi-
remia (strong, high). If QNAT is not available, antigenemia is
a less desirable alternative.
• We recommend either plasma or whole blood specimens for
QNAT, with an appreciation for the differences in viral load
values, viral kinetics and assay performance characteristics.
(strong, high). Neither the specimen type nor the assay should
be changed when monitoring patients.
• Despite reporting in IU/mL, we recommend that viral load
values are not directly compared across centers and/or labora-
tories unless identical testing reagents and procedures can be
assured or equivalence has been documented (strong, high).
• We recommend that only changes in viral load exceeding
0.5 log10 IU/mL (threefold) are considered to represent clini-
cally significant differences in DNAemia (strong, low).
• Although harmonization of QNAT has improved, universal
thresholds for therapy or treatment endpoints have not been
established and current published thresholds remain assay-
specific. Accordingly, we recommend that centers establish
their own thresholds and audit clinical outcomes to verify
the thresholds used (strong, moderate).
• Wedo not recommend surveillance of CMVDNAemia during
routine prophylaxis.
• We recommend when monitoring response to antiviral ther-
apy, that QNAT is performed weekly (strong, moderate).
• With the use of highly sensitive QNAT (LLOQ <200 IU/mL),
we suggest discontinuing therapy after 1 result is less than
the LLOQ. If this approach is used, confirmatory testing
should be done 1 week after discontinuing therapy. If the as-
say is not highly sensitive, then 2 consecutive undetectable
(negative) results are needed to discontinue therapy (weak
and moderate).
• We recommend histology coupled with immunohistochemis-
try for the diagnosis of tissue-invasive disease. Histopathologic
examination of tissue should routinely include immunohisto-
chemistry for CMV (strong, moderate).
Future Directions
• Directly compare QNAT monitoring in plasma, whole blood,
and BAL specimens with respect to disease prediction and
monitoring response to therapy with an emphasis on using
commercially available testing systems.
• Determine commutability and harmonization using theWHO
International Standard for whole blood and BAL.
• To improve harmonization of QNAT, determine the viral
form (virions, fragmented, or genomic CMV) and viral kinet-
ics in whole blood.
• Assess the role of digital QNAT to improve standardization of
copy number assignment for secondary standards.
• Once viral load tests are harmonized, establish thresholds and
kinetics for DNAemia for initiating preemptive therapy.
• Compare the performance characteristics of the different sero-
logic tests and assess the utility of CMI assays and QNAT
using a variety of sample types for the interpretation of
passive immunity.
• Standardized/optimize/harmonize tests measuring neutraliz-
ing antibody in epithelial cells and fibroblasts when used to
evaluate vaccine responses, characterize immunoglobulin prep-
arations and evaluate antibody levels as a biomarker for
predicting disease risk.
• Further validate nonseroconversion at 12 to 18 months after
antiviral prophylaxis as a marker of nontransmission of
donor-derived CMV infection in CMV mismatched patients.
• Further evaluate the usefulness of binding and neutralizing an-
tibody (epithelial and fibroblast) measurements pretransplant
in CMV seropositive patients and posttransplant in CMV
mismatched patients as a predictor of disease risk.
IMMUNOLOGIC MONITORING FOR CMV
Innate Factors
Both innate and adaptive immune mediators are necessary
for control of CMV after transplantation.73,74 Innate im-
mune factors include Toll-like receptors in which single nu-
cleotide polymorphisms are associated with an increased
risk of CMV disease.75 Polymorphisms in genes for mannose
binding lectin (MBL) associated with low MBL production
and ficolin-2 may also be associated with increased risk of
CMV disease.76-78 A multicenter study has recently demon-
strated that patients with lower complement C3 levels
(<80 mg/dL) early (7 days) after transplantation have a
greater risk for CMV disease.79 Transplant recipients with
an IL-28B single nucleotide polymorphism were found to
be at significantly less risk of CMV replication.80 Conversely
those with a CCL8 promoter polymorphism showed in-
creased risk of CMV replication.81 In addition, lower levels
of natural killer (NK) cells early after transplantation are a
risk factor for CMV disease in heart and liver recipients.82,83
Inhibitory NK cell KIR genotypes have been described as a
predisposing factor during CMV reactivation in kidney
transplantation while B-type NK cell haplotypes containing
activating NK cell KIR genes were shown to be protective
in organ recipients.84-86 γδ (gamma-delta) T lymphocytes
that have both innate and adaptive characteristics have been
reported to have a role in the immune response to CMV in
transplantation.87,88 Longitudinal kinetic surveillance of
Vδ2− γδTcells in kidney recipients has been suggested to pre-
dict CMV infection resolution.89 Although the above asso-
ciations are important for the pathogenesis of CMV,
changes in CMV management based on these factors have
not been studied.
Nonpathogen-specific Adaptive Immunity
Adaptive or acquired immune responses of B and T lym-
phocytes are critical in controlling CMVreplication. Methods
to monitor the adaptive immune response to CMVmay allow
for early identification of patients at increased risk of viral rep-
lication. B cells are important in the humoral response to
CMV, producing neutralizing antibodies that primarily target
glycoprotein B (gB) and gH90 and the pentameric gH/gL/
UL128/UL130/UL131A complex.91-93 There is emerging
evidence that a significant number of posttransplant patients
develop hypogammaglobulinemia (26%-70% in some se-
ries94-97). A recent meta-analysis demonstrated that severe
hypogammaglobulinemia during the first year after trans-
plant significantly increased the risk of CMVdisease.Moder-
ate and severe (IgG, < 400 mg/dL) hypogammaglobulinemia
have been demonstrated to be a risk factor for CMVinfection
in heart and lung transplant recipients in single-center studies
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performed in patients with various induction immunosup-
pressive protocols.79,98,99 A multicenter prospective study
showed that heart recipients with moderate hypogamma-
globulinemia at day 30 after transplantation were at higher
risk of CMV disease.79 Severe IgG hypogammaglobulinemia
has been associated with CMV disease refractory to antiviral
therapy.100 Interventional studies in heart transplant recipi-
ents using CMV immunoglobulin (CMV Ig) or intravenous
immunoglobulin replacement have shown that IgG replace-
ment may prevent CMV disease.101-103 Retrospective studies
have suggested that replacement of IgG levels by use of IVIG
in heart recipients with IgG hypogammaglobulinemia de-
tected at the time of CMV disease including refractory cases
was associated with better outcomes.104,105 Despite the evi-
dence of IgG replacement therapy in thoracic transplant re-
cipients, the link of hypogammaglobulinemia with CMV
risk remains controversial in kidney and liver recipients.96,106
The potential role of lymphopenia, a commonly used bio-
marker in clinical practice, as a risk factor for development of
CMVinfection has been evaluated. In amultivariate analysis,
pretransplant lymphopenia was the strongest independent
predictor of CMV disease among 276 liver transplant pa-
tients.107 Lymphocyte counts also tended to be lower in pa-
tients who have recurrent CMV infections.108
Nonpathogen-specific immune function assays are also
available. The ImmuKnow (Cylex/Viracor-Eurofins, USA)
assay is not specific for CMV. This assay, which is commer-
cially available in the United States and in some European
countries, measures overall immune function and serves as
a marker of immunosuppression by determining the amount
of ATP produced by CD4+ Tcells in response to whole blood
stimulation by phytohemagglutinin. However, there are no
studies indicating whether this assay is predictive of CMV
DNAemia or disease. Therefore, there is insufficient evidence
to recommend this assay forCMVprediction. Another immune
function assay under development is the QuantiFERON-
Monitor (Qiagen, USA) which measures global immune
function after stimulation of whole blood with a lyosphere
containing R848 and anti-CD3.109 In general, however,
CMV-specific immune-based assays are likely to have greater
clinical utility than a nonspecific assay.
The complexity of the immunological response to control
CMV infection makes it unlikely that any single marker will
be highly predictive of risk. The combined use of distinct bio-
markers has been suggested to be a better approach than the
use of single markers including biomarker combinations and
gene profiles.110 Immunological scores including distinct bio-
markers have been suggested as other option to identify pa-
tients at higher risk of CMV infection.98
CMV-specific Immune Monitoring Assays
Immune monitoring of CMV-specific T-cell responses can
predict individuals at increased risk of CMV disease post-
transplant and may be useful in guiding prophylaxis and pre-
emptive therapies. There is a variety of CMV-specific T-cell
assays. Many assays have nowmoved from the experimental
to the clinical setting. The majority of assays rely on the de-
tection of IFN-γ after stimulation of whole blood or periph-
eral blood mononuclear cells (PBMC) with CMV-specific
antigens or overlapping peptides.111,112 In addition to IFN-γ,
other markers, including IL-2, TNF-α, CD107, programmed
death-1 (PD-1), and CD154 have been used to correlate
CMV-specific T-cell responses with the risk of CMV infec-
tion. The expression of chemokines CCL8 and CXCL10
has also been associated with CMV control in patients with
CMV DNAemia whereas expression of CCR6, a chemokine
receptor, predicted CMV reactivation.81,90,113
The expert panel was of the opinion that an ideal assay
should provide both quantitative and functional information
on CMV-specific CD4+ and CD8+ T cells. For clinical appli-
cation, an assay should ideally be simple to perform, inexpen-
sive, highly reproducible, and amenable to either widely
available platforms or shipping to specialized reference labo-
ratories. Each of the immune monitoring assays has specific
advantages and limitations and has been studied in various
clinical applications to predict disease or viremia (Table 2).
TheQuantiFERON-CMVassay is a commercially available
kit (CE marked in Europe) and is an enzyme-linked immuno-
sorbent assay (ELISA)-based IFN-γ release assay detecting
CD8Tcells after peptide stimulation. The assay has been eval-
uated in clinical studies of transplant patients at high risk of
CMVand shown to be predictive of disease.114-117 Moreover,
a negative test before transplantation may aid in predicting vi-
remia in the posttransplant period118 or the dynamics of T-cell
responses may be used as a monitoring tool in a preemptive
setting.119 In a small cohort of transplant recipients with low
level CMVDNAemia, a positive assay was predictive of spon-
taneous clearance.120 Amain drawback stems fromdifficulties
in interpretation if a patient does not respond to the mitogen
control. Nonresponse to mitogen may potentially be a marker
for global immunosuppression, and has been associatedwith a
subsequent higher incidence of CMV disease.116 Test sensitiv-
ity decreases in lymphopenic patients because an adequate
number of cells are required for the production of IFN-γ.
The enzyme-linked immunosorbent spot (ELISpot) assay
quantifies both CD4+ and CD8+ T cells producing IFN-γ in
response to CMV. Purified PBMCs are stimulated with
CMV-specific peptides or whole antigen lysates; IFN-γ is
then captured, detected, and quantified using a labeled anti-
body. As with the QuantiFERON assay, a mitogen control
may indicate general T-cell responsiveness. The ELISpot as-
say cannot differentiate between CD4+ and CD8+ T cells.
Various in-house ELISpot assays have been evaluated and
shown to be predictive of disease and viremia.121-125 Studies
have used arbitrary cutoffs for defining positive responses
that range between 5 and 50 spot-forming cells per 200000
PBMC. Others have suggested that kinetics of ELISpot re-
sponses are better for risk stratification.126 ELISpot assays
have also been used in the pretransplant setting to predict
posttransplant outcomes.126,127 One study showed that stim-
ulation with an overlapping peptide pool of IE-1 in the
pretransplant period predicted CMV in the posttransplant
period in CMV seropositive patients.127 However, another
smaller study found no predictive value of pretransplant
CD4 and CD8 responses.128 A commercial ELISpot assay
(T-Track CMV, Lophius Biosciences, Germany) has recently
received CE marking in Europe.129,130 Another assay (T-
SPOT.CMV,Oxford Immunotec, UK, CEmarked in Europe)
is used as a laboratory developed test (LDT) in the United States.
Many studies that have analyzed CMV-specific T-cell re-
sponses have used intracellular cytokine staining (ICS) for
IFN-γ using flow cytometry. Whole-blood or isolated PBMCs
are stimulated with CMV peptides or CMV lysate. If whole
antigen lysate is used, the assay is not HLA-restricted and
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knowledge of patient HLA type is not required. Stimulated
cells are stained with monoclonal antibodies directed against
IFN-γ. This technique is fast, versatile, and can be expanded
to include other cytokines and cell surface molecules. Unlike
ELISpot or QuantiFERONassays, ICS can thus provide both
quantitative and qualitative characteristics of CMV-specific
T cells. Clinical studies have shown that this technique can
predict both CMV disease and viremia. Several studies in
SOTRs showed an increased risk of CMV disease in patients
with low levels of specific T-cell immunity.131-134 Similarly,
the absence of anti-CMV T-cell response by this technique
correlates with the inability to clear viremia.131,134,135 Stable
levels of CMV-specific CD4+ T cells were associated with
lower risk of CMV replication.131,134 The development of
T-cell immunity especially polyfunctionality has also been
shown to be associated with freedom from CMV disease
after lung transplantation.136-138 The predictive value for vire-
mia may be improved when the analysis of IFN-γ is combined
with other cytokines, such as IL-2, and additional markers,
such as PD-1.139,140 Advances in flow cytometry, such as the
ability to test for several markers at once (eg, with CyTOF
technology), can increase our understanding of immune con-
trol although these are available in the research setting only.
Major histocompatibility complex (MHC)-multimer based
assays directly stain peptide-specific T cells using peptide-
conjugated MHC class I tetramers or pentamers. They can
determine CD8 T-cell responses but are epitope-specific and
require knowledge of the patients’HLA type.Multimer assays
have only been shown to predict CMV viremia when com-
bined with analysis of surface markers, such as PD-1.141,142
Both ICS and MHC-multimer staining require a fluorescence-
activated cell sorting facility, which may limit widespread
use in transplant centers.
Several clinical studies have now been published that have
used immune monitoring to determine risk of CMV disease
and viremia. The majority of studies have measured IFN-γ
alone or in combination with other cytokines or cell-surface
molecules and included both seropositive and seronegative
recipients. The frequency of monitoring in these studies has
been variable; high-risk patients were generally monitored
starting at the end of prophylaxis and those undergoing preemp-
tive therapy were screened weekly to monthly for up to 1 year
posttransplant. Therefore, data are accumulating that suggest im-
mune monitoring may be considered in combination with viral
loadmonitoring to improve assessment of the individual's ability
to control CMV. Data are also accumulating for measuring im-
mune function in the pretransplant setting. Donor testing for
CMV has also been performed using immune monitoring plat-
forms although indeterminate results are frequently seen depend-
ing on the assay.23 Clinical utility studies demonstrate that
alteration of patient management based on the results of an
immune-based assay is feasible, safe, and cost-effective are
TABLE 2.
Advantages and limitations of various assays for immune monitoring of CMV
Assay Advantages Limitations Comments Predict viremia Predict disease
ICS Whole blood assay with low blood
volume (1 mL) or PBMC Short
incubation time Results available
after 8 hours Identification of
CD4+ and CD8+ T cells Knowledge
of HLA not necessarily required
Quantitative and qualitative
characterization
Needs access to a flow
cytometer
Not standardized
Most data available with
this technique Potential
to freeze PBMCs and
ship to reference
lab for testing
Yes Yes
QuantiFERON-CMV
(Qiagen, USA)
Whole blood assay with low blood
volume (3 mL)
Simple to perform Results available
after 30-40 hours Can be done in
any center and stimulated plasma
can be sent to reference lab
CD8+ responses only.
Sensitive to lymphopenia.
Rare patients whose
HLA types are
not covered in assay
Approved in Europe Yes Yes
ELISpot Identifies both CD4+/CD8+ T cells
Knowledge of HLA not necessarily
required Results available
after 30-40 hours
Need for purified PBMC
from 10 mL blood
(in reality 5-10 mL)
Cannot differentiate
CD4+ and CD8+
T cells
Not standardized
Potential to freeze PBMCs
and ship to reference lab
for testing; Commercial
availability (T-Track CMV,
Lophius CE marked in
Europe; T-SPOT.CMV is
LDT in U.S.) and CE marked
in Europe
Yes Yes
MHC multimer
staining
Fast assay (1-2 h) Whole blood
assay with low blood volume
(0.5-1 mL) or PBMC
CD8+ responses only
Needs access to a flow
cytometer HLA and
epitope-specific.
No information about
function unless
combined with ICS
Not standardized
Unlikely to be used on a
widespread basis
No, Only in combination
with functional or
phenotypical markers
No
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ongoing. Recently, an interventional study using the
QuantiFERON-CMV assay to stratify patients in receiving
secondary prophylaxis showed that CMV-specific immune
function could bemeasured in real time and used tomake clin-
ical decisions.143 This study showed that it was safe to discon-
tinue treatment antivirals in patients with CMV-specific
immunity without the need for secondary prophylaxis. Inter-
ventional studies of primary prophylaxis are underway. Poten-
tial clinical applications for immune-based assays are
summarized in Table 3.
Adoptive T-cell Therapy
Several case reports now exist demonstrating the clinical use
of CMV-specific T cells for resistant/refractory CMV infection
in organ transplant recipients.144-148 In general, CMV-specific
T cells undergo expansion with CMV synthetic peptides or vi-
ral lysate and are then infused into the recipient. This therapy
has led to reconstitution of viral immunity, reduction in CMV
viral loads or resolution of CMV disease. Cells can be ob-
tained from the transplant recipient (autologous); however,
the process of generating effector cells can take several weeks.
Therefore, there is increasing interest in “off the shelf” T cells
using HLA-matched third-party banked cells. This method
could also allow generation of cells active against multiple vi-
ruses including CMV, Epstein-Barr virus (EBV), and adenovi-
rus. There is a larger breadth of experience usingCMV-specific
Tcells in the hematopoietic stem cell transplant (HSCT) field,
which has shown varying degrees of efficacy with no asso-
ciation with graft versus host disease.149,150 Commercia-
lization of third-party CMV-specific T cells may lead to
increasing use of this modality for resistant/refractory CMV
in SOTRs.151,152 Safety and efficacy studies will be needed.
CMV Vaccine
Several CMV vaccines are under development, but none
are currently available for routine clinical use. Types of
vaccines include live attenuated, recombinant/chimeric viral
vectors, recombinant subunit, or gene-based vaccines.153 A
live attenuated vaccine based on the Towne strain of CMV
was found to be safe during clinical testing but had a sub-
optimal antibody response and while CMV disease was
attenuated, the vaccine failed to prevent infection.154 A re-
combinant gB vaccine withMF59-adjuvant was shown to in-
duce neutralizing antibodies155 and prevent infection.156 In a
recent study, this vaccine was administered in a 3-dose sched-
ule to both CMV seropositive and seronegative transplant
candidates.157 During follow-up, the vaccine reduced overall
days of CMV viremia and number of days of antiviral ther-
apy. A trial with a gB/pp65-based DNA plasmid vaccine in
HSCT recipients was completed. This vaccine was adminis-
tered as 1 pretransplant dose and 5 posttransplant doses. It
showed a significant reduction in viremia versus placebo as
well as a reduction in the number of CMV episodes.158 A
multicenter clinical trial for the gB/pp65-based DNAvaccine
was conducted inCMVmismatched transplant recipients but
did not show a significant reduction in CMV viremia needing
antiviral therapy.159 Recently, a peptide-based CMV vaccine
(CMVPepVax) has been used in clinical trials. This vaccine is
developed using the HLA-A*201-restricted pp65 CD8 T cell
peptide epitope which is fused with the P2 peptide epitope of
tetanus toxin and mixed with TLR9 agonist just before ad-
ministration. This vaccine was given using a 2-dose schedule
to HSCT patients in a small randomized trial and showed a
significant reduction in CMV viremia.160 An alphavirus rep-
licon vector system has been used to produce viral particles
expressing gB and pp65/IE-1 fusion protein; initial studies
in mice and rabbits have shown the development of neutral-
izing antibodies161 and a phase I trial has been done. Other
vaccines include canarypox gB and pp65 vaccines that pro-
duce T-cell responses and neutralizing antibodies.162,163 An
adenoviral chimeric vaccine-based replication deficient
TABLE 3.
Potential clinical uses and management based on CMV-specific immune monitoring
Clinical settings Viral load Immune monitoring resulta Action Interpretation
Pretransplant
Pretransplant R+ Neg Prophylaxis or surveillance Indicates low level protection
Pretransplant Seropositive patients
with potential passive antibodies
Neg Passive immunity; T cells are
not transferred
Pos True Infection
Posttransplant prophylaxis
End of prophylaxis Pos Stop prophylaxis Indicates protection
Neg Continue prophylaxis or stop
prophylaxis and do surveillance
Indicates lack of protection
Posttransplant preemptive therapy
Asymptomatic R+ patients
(>1 month posttransplant)
Neg Pos Continue surveillance Low risk, indicates protection
Neg Neg Close surveillance Increased risk, indicates lack
of protection
Pos Pos No treatment; close monitoring Low risk, indicates sufficient immunity
Pos Neg Treatment Indicates lack of protection
End of treatment Neg Pos Stop treatment Low risk of relapse,
sufficient immunity
Neg Neg Secondary Prophylaxis High risk of relapse, lack
of protection
a Positive (or Reactive) immune monitoring result suggests a threshold has been established; viral load negative means below lower limit of quantitation. Limited information in heart and lung transplant recipients
and pediatric recipients.
Neg, negative; Pos, positive.
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adenovirus encoding gB andmultiple CMVepitopeswas able
to produce a robust cellular response and neutralizing anti-
bodies in mice.164 In general, CMV vaccines have reached
human studies with clinical endpoints. However, because
CMVvaccines are still in early stages of clinical development,
no specific recommendation for vaccine use are made.
Consensus Statements and Recommendations
• Host genetic markers and immune parameters, such as low
lymphocyte counts, complement levels and/or NK cell counts
as well as T cell immune functional assays, have shown asso-
ciation with higher incidence of CMVinfection.Measurement
of such parameters could potentially be used to inform the risk
of infection although no interventional studies using these
have been performed.
• CMV vaccines are in preclinical, phase I and phase II trials.
The primary goal of a CMV vaccine should be to prevent or
modulate CMV replication and/or CMV disease. Surrogate
endpoints (eg, reduction in viral replication, T-cell immunity)
can be used to evaluate vaccine immunogenicity and efficacy.
• T-cell therapies should be further evaluated for resistant/
refractory CMV.
• IgG hypogammaglobulinemia is associated with an increased
risk of CMV disease after transplantation. Measurement of
total immunoglobulins is suggested in situations where
CMV is difficult to control (weak, low).
• CMV-specific cellular immune monitoring has been shown to
predict CMVinfection in the pretransplant and posttransplant
settings in prospective observational, multicenter studies. Ac-
cordingly, assessment of CMI can be used to inform risk of
CMV (strong, moderate). Interventional studies to determine
precise clinical utility of CMI are ongoing.
Future Directions
The following future research directions are important
for the further development of immune monitoring and
CMV vaccines:
• Immune monitoring assays should continue to be standard-
ized. Cut-off values need to be established for ELISpot and
ICS assays. In addition, regulatory T cells and γδ T cells
may have predictive value for DNAemia and should continue
to be studied for incorporation into immune monitoring
strategies.
• Clinical utility studies of immune monitoring are needed that
demonstrate that alteration of patient management based
on the results of an immune-based assay is feasible, safe,
and cost-effective.
• Studies are also needed to determine the comparative perfor-
mance of immune monitoring assays in the prediction of
CMV viremia/disease.
• Further data are needed for the safety and feasibility of adap-
tive T-cell therapy in organ transplantation.
• For further development of CMV vaccines, the expert panel
was of the opinion that (i) given the high frequency of disease
in D+/R− transplant recipients, vaccines should be evaluated
specifically in this group; (ii) vaccination may also reduce bur-
den of disease or impact the course of latent CMV infection in
seropositive patients; vaccination trials should therefore focus
on this group also; and (iii) vaccine studies should include an
evaluation of both humoral and cellular immunities where ap-
plicable as well as longevity of responses.
PREVENTION
Given the high frequency of primary CMV infection and
reactivation, prevention strategies are of paramount impor-
tance as they augment transplant clinical success and out-
comes, by decreasing the risk of CMV infection and disease,
as well as the associated “indirect effects.”Universal prophy-
laxis and preemptive therapy are the main approaches for
prevention. An additional strategy that combines both of
these approaches is “surveillance after prophylaxis” (termed
“hybrid approach” in prior guidelines). Herein, we cover
both standard prevention methods (Table 4), as well as addi-
tional tactics. Additional information is available on thresholds
for initiating treatment, and we have a better understanding of
the lower risk of CMV infection with mammalian target of
rapamycin (mTOR) inhibitors in CMV seropositive recipients.
Universal Prophylaxis
Universal prophylaxis entails the administration of antivi-
ral medication to all patients or a subset of “at-risk” patients,
starting within 10 days after transplant and continuing for a
finite period (ie, 3-6 months). Acyclovir, valacyclovir, intra-
venous ganciclovir (GCV), oral GCV, and valganciclovir
(VGCV) have all been studied for universal prophylaxis.
Valganciclovir is currently the most commonly used drug
for prophylaxis. In early studies, GCV prophylaxis was
found to be more effective than acyclovir.165 Equivalent effi-
cacy was found in a large study of D+/R− transplant patients
comparing oral GCV to VGCV (PV16000); however, in small
subgroup analysis, tissue invasive disease was noted at in-
creased incidence in liver transplant patients who received
VGCV.166 Oral GCV is no longer available. High-dose
TABLE 4.
Comparison of prophylaxis versus preemptive therapy
Prophylaxis Preemptive therapy
Early CMV DNAemia/ infection Rare Common
Prevention of CMV disease Good efficacy Good efficacy
Late CMV (infection/disease) Common Rare
Resistance Uncommon Uncommon (with weekly testing)
Ease of implementation Relatively easy More difficult
Prevention of other herpes viruses Prevents HSV, VZV Does not prevent
Other opportunistic infections May prevent Unknown
Costs Drug costs Monitoring costs
Safety Drug side effects Less drug toxicity
Prevention of rejection May prevent Unknown
Graft survival May improve May improve
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valacyclovir has been shown to be effective for prophylaxis
in kidney transplant recipients.167
Late-onset CMVdisease, or disease occurring after the dis-
continuation of prophylaxis, has occurred in all studies eval-
uating universal prophylaxis. Late CMV disease is likely
related to a lack of CMV-specific CMI in the setting of ongo-
ing immunosuppression. Risk factors for late-onset disease
include D+/R− serostatus, shorter courses of prophylaxis,
higher levels of immunosuppression, certain types of trans-
plant (eg, lung), and allograft rejection.168,169 In the PV16000
study, where 3 months of prophylaxis was used, 18% had
late-onset CMV disease by 12 months (~30% when includ-
ing investigator treated disease).166 This has led to studies
evaluating longer durations of prophylaxis (see below).25
Preemptive Therapy
Effective preemptive therapy (PET) involves monitoring
for CMV in blood at regular intervals (ie, CMV viral load
checked weekly) to detect early viral replication. Once a
predetermined assay threshold is achieved (optimally before
the development of symptoms), antiviral treatment is begun,
which should prevent progression to clinical disease. Better
availability and standardization of assays have made this ap-
proach more feasible. Nonetheless, given the variability
among diagnostic specimens (whole blood versus plasma)
and testing platforms,43,170 a universal threshold for starting
therapy cannot be defined. It is likely that optimal thresholds
are different among different at-risk groups. There was
strong consensus that a lower threshold should be used with
D+/R−, as the use of higher thresholds may result in insuffi-
cient time to begin treatment for CMV and higher rates of
disease.171 For example, 1 study demonstrated a median vi-
ral load doubling time of 1.54 days (range, 0.55-5.5) in D+/
R− compared with 2.67 days (range, 0.27-26.7) in the D+/
R+ recipients (P < 0.0001).172 Although prior guidelines
mentioned that some experts, given the unpredictable viral
kinetics (especially in D+/R−), recommended starting treat-
ment with any detectable DNAemia,172,173 with increasingly
sensitive assaysmany experts felt that very low results should
not always result in initiation of treatment, even in D +R− re-
cipients (see Diagnostics).
Advantages of preemptive therapy include a reduced rate
of late CMV, selective drug use, and decreased drug cost
and toxicities. Preemptive therapy can be difficult to coordi-
nate, given the logistics of weekly testing, reviewing results,
initiating therapy rapidly after positive assays, and perform-
ing subsequentmonitoringandmanagement. Preferably, 1 as-
say and specimen type, (whole blood or plasma) should be
used for an individual patient to ensure comparability of re-
sults. Preemptive therapy may not prevent the indirect effects
of CMV infection, including effects on graft and patient sur-
vival; studies have demonstrated conflicting data.174-177 Sec-
ond episodes of replication are observed in about 30% of
those treated for CMV DNAemia,178 so the specter of late
CMV remains. Patients managed with the preemptive ap-
proach should receive oral acyclovir (or similar) for the pre-
vention of disseminated herpes simplex infections.179
Universal Prophylaxis Versus Preemptive Therapy
Four randomized trials directly compared universal pro-
phylaxis with preemptive therapy in renal transplant recipi-
ents.174-177 In studies using weekly monitoring for 4 months
posttransplant with reported high compliance rates, no differ-
ence in the incidence of CMVdisease or intragraft CMVinfec-
tion was found compared to universal prophylaxis.174,175,180
Comparable long-term graft survival was observed with pre-
emptive therapy with a similar incidence of other CMV indi-
rect effects181; PET was better when compared with
valacyclovir prophylaxis.182 It should be noted that less fre-
quent screening (ie, less than weekly) resulted in higher rates
of CMV disease and inferior long-term graft survival com-
pared to prophylaxis.176,177
There is no randomized study directly comparing pre-
emptive approach and prophylaxis in liver transplantation.
Several meta-analyses with significant numbers of liver trans-
plant recipients have confirmed similar efficacy in prevention
of CMVdisease and no difference inmortality, graft loss, and
acute rejection. As expected, CMV DNAemia is more com-
mon with preemptive therapy, whereas late-onset CMV
DNAemia or disease and neutropenia is more common with
prophylaxis.183-185 Other herpes viral infections are more
commonwith the preemptive strategy.185 A large prospective
national cohort study found an increased risk of graft loss in
patients managed by preemptive strategy, with notably short
follow-up (~1 year).186 In contrast, the 4-year pooled analy-
sis of patients included in 2 randomized studies did not iden-
tify themode of CMVprevention (preemptive vs valacyclovir
prophylaxis vs VGCV prophylaxis) as an independent risk
factor of graft loss. Cytomegalovirus DNAemia with viral
load of more than ~2000 IU/mL in whole blood was a strong
predictor of graft loss.187
Comparison of approaches among D+/R− patients is lim-
ited by a low proportion of the D+/R− group in randomized
trials.174-176 Nevertheless, the results seemed to be compara-
ble even in higher risk patients. Both a subanalysis of a cohort
study186 and meta-analysis185 showed a similar incidence of
CMV disease in D+/R− group. Repeated courses of preemp-
tive therapy are sometimes required in high-risk patients.172
In summary, using a preemptive approach with once weekly
CMV surveillance for 3 to 4 months and universal prophy-
laxis are both comparable methods of CMV disease preven-
tion for D+/R− and/or R+ kidney and liver transplant
recipients.
The preemptive approach is not well studied in nonrenal
and nonliver transplant recipients, thus we suggest universal
prophylaxis in D+/R− heart and lung transplant recipients,
given the high rates of CMV disease and CMV indirect ef-
fects.188,189 There are no studies available to prove efficacy
of preemptive approach in R+ lung transplant thus univer-
sal prophylaxis is preferred in the majority of lung
transplant centers.190
Surveillance After Prophylaxis
For prompt detection of evolving CMV infection (and to
decrease the risk of late CMV), the majority of the experts
utilize surveillance after prophylaxis at least sometimes. Thus
far, research does not support the use of a surveillance after
prophylaxis approach,191-194 although studies are limited
by short monitoring periods, long interassay intervals, and
other methodological issues. Use of surveillance after pro-
phylaxis may be considered in patients at increased risk for
postprophylaxis CMV disease. Based on the experience with
preemptive therapy, the value is probably greatest if done
© 2018 Wolters Kluwer Kotton et al 909
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
weekly for 8 to 12 weeks after the end of prophylaxis
(weak, low).
Thresholds for Triggering Preemptive Therapy (or
Surveillance After Prophylaxis)
Specific viral load thresholds for triggering therapy in
asymptomatic patients have not yet been defined, in part be-
cause of the significant interassay and interinstitutional vari-
ations seen with CMV DNA testing, along with the variable
impact of immunity (primary versus reactivation infection,
intensity of immunosuppression, impact of various immuno-
suppressive agents used for induction and maintenance).
Although low viral loads are likely to be more clinically sig-
nificant in those at higher risk for infection, using too low
of a viral load threshold can result in unnecessary treatment.
Programs may wish to define their own local thres-
holds based on their assay, specimen type, and patient risk
factors. Table 5 highlights recent thresholds used in various
research studies.
Some groups have suggested that the kinetics of the CMV
DNA doubling time may be a valuable diagnostic parameter
for PET, given that real-time quantitative reverse transcrip-
tion PCR (qRT-PCR) assays show linearity above their limit
of quantification, andmay allow for direct comparison of re-
sults obtained across centers using similar or different qRT-
PCR assay.199-201 Viral replication kinetics have shown that
viral load in the first surveillance sample and the rate of in-
crease defines the risk of subsequent CMV disease; this risk
is different in CMV-naïve patients undergoing primary
CMV infection versus those with prior immunity.30,202 This
approach requires more frequent testing (at least biweekly).
Optimal Duration of Prophylaxis
Seropositive recipients generally need shorter courses
of prophylaxis compared with D+/R−. Risk factors for late-
onset disease include D+/R− serostatus, shorter courses of
prophylaxis, higher levels of immunosuppression, and
allograft rejection.168,169,203 In the Improved Protection
Against Cytomegalovirus in Transplantation study, a de-
creased risk of CMV disease was seen in patients given
200 days of prophylaxis (21.3%) in D+/R− kidney recip-
ients compared with those given 100 days of prophylaxis
(36.8%).169 Extending CMV prophylaxis from 6 to
12 months in pediatric kidney-transplant patients, however,
did not prevent CMV infection or disease.204 Long courses
of prophylaxis with VGCV are associated with higher rates
of leukopenia and greater cost.
Longer prophylaxis may be warranted in D+R− lung re-
cipients. In a study of 136 lung transplant recipients (includ-
ing both D+/R− and R+), VGCV prophylaxis for 12 months
versus 3 months was associated with a significantly lower
CMVinfection and disease incidence.205 In a study of 6months
of prophylaxis, almost 50% of D+/R− lung transplant pa-
tients developed late-onset CMV infection or disease.203
Many programs have moved towards 6 to 12months of pro-
phylaxis.188,203,205-207 Serostatus of both donor and recipi-
ent at the time of transplant may help guide the duration of
prophylaxis; after lung transplant and 6 months of prophy-
laxis, 34%of D+/R+ and only 6%of D−/R+ developed infec-
tion or disease.203 Some programs continue prophylaxis
indefinitely after lung transplant, although there is insuffi-
cient data to support this approach.208,209
Valacyclovir
High-dose valacyclovir is effective for prevention of CMV
disease and CMVDNAemia in both D+/R− and D±/R+ renal
transplant recipients.167,210 Apart from comparable efficacy
to oral GCV prophylaxis,211,212 a recent randomized study
showed similar rates of CMV DNAemia compared with
VGCV prophylaxis.213 A lower incidence of acute rejection
and higher rate of polyomavirus viremia was observed with
VGCV.213,214 Disadvantages of valacyclovir include high pill
burden and neuropsychiatric side effects, which may be de-
creased if valacyclovir initiation is postponed in patients with
TABLE 5.
Thresholds used in various research publications (published since last guidelines)
Population Threshold Comments Reference
High risk D+R−
39 D+R− SOT (23 kidney,
15 liver, 1 heart)
1500 IU/mL in plasma No episodes of symptomatic CMV disease were diagnosed
in patients with viral loads below 1500 IU/mL.
Very high rate of infection (36/39).
195
Mixed risk D+R− and R+
689 kidney (n = 368) and liver
(n = 321), 11% D+R−, 71% R+
3000 copies/mL in whole blood, twice a week
(same group later converted this to
2520 IU/mL,196 see below)
More of a study of preemptive therapy and
effect of immunity than analysis of threshold
172
3/45 D+R− 42/45 D+R+ SOTR 2275 IU/mL (2500 copies/mL) in plasma This threshold allowed for discrimination between
self-clearing infections and those requiring therapy.
Focus of study on use of CMV DNAemia vs antigenemia.
197
59 Kidney, liver, HSCT patients
(minority were higher risk)
2520 IU/mL (3000 copies/mL) of whole blood Whether antiviral treatment needed for PET @ 2520 IU/mL
(yes); not an analysis of best threshold, but whether
2520 IU/mL is an effective threshold (yes).
196
Lower risk R+
252 R+ SOTR 3983 IU/mL threshold resulted in 99.6% NPV,
“the great majority of patients at lower risk
will not develop CMV disease without specific
antiviral therapy”
Analysis of best threshold; single center and
only seropositive recipients
198
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delayed graft function. Advantages of valacyclovir include
less myelotoxicity and lower cost.210,213,215
New Drugs for CMV Prevention
New potent oral drugs would be useful additions to
the currently available therapies for CMV prevention. Three
compounds are in various stages of late development.
Letermovir inhibits the viral terminase enzyme complex
encoded by UL56, does not share cross-resistance with
GCV,216 and has both an oral and intravenous formulations.
Letermovir has demonstrated efficacy and safely in HSCT
patients217,218 and is commercially available for use as pro-
phylaxis in HSCT recipients. A phase 3 trial for letermovir
prophylaxis in kidney transplant recipients is just beginning.
Maribavir is an oral drug that inhibits CMVUL97 and plays
a role in inhibition of viral maturation and egress. It also ap-
pears to have a good safety profile with no evidence of
myelosuppression or nephrotoxicity. Early studies for use in
prophylaxis after SOT failed to demonstrate efficacy219; on-
going studies are evaluating higher doses for treatment, either
for DNAemia or for patients with refractory/resistant CMV.
Neither letermovir nor maribavir covers HSV and VZV, so
additional antiviral prophylaxis may be needed. Brincidofovir
is a lipid conjugated prodrug of cidofovir (CDV) with broad
antiviral efficacy, including potent antiherpesvirus activity,
through inhibition of viral DNA polymerase. It has not been
evaluated for prophylaxis in SOT patients. Although there
was preliminary evidence of benefit in HSCT patients,220 sig-
nificant gastrointestinal toxicity in the phase III trial led to
the discontinuation of a planned prophylaxis trials in kidney
transplant recipients. An intravenous formulation is being
developed in hopes of reducing toxicity.
Prevention Strategies for CMV D−/R−
When both donor and recipient are seronegative for CMV,
there is minimal risk of CMV infection, and routine preven-
tion of CMV is not recommended. Antiviral prophylaxis
against other herpes infections (especially disseminated vari-
cella and herpes simplex) with acyclovir, famciclovir, or
valacyclovir should be considered.
Prevention During (Massive) Blood Transfusion
To avoid transfusion-transmitted CMV, we recommend
the use of leukoreduced or CMV-seronegative blood prod-
ucts (strong, moderate). The highest risk is in D−/R−, al-
though there may be a contribution in R+. Additional
clinical benefit of combining these 2 strategies is not avail-
able.221 Extensive transfusion of blood products increases
the risk of CMV disease (especially if not CMV screened or
leukoreduced), and transplant centers may wish to monitor
such recipients with weekly viral load testing or give CMV
prophylaxis (weak, very low).
Secondary Prophylaxis and Recurrent Infection
There have been no prospective randomized trials of
secondary prophylaxis for prevention of recurrent CMV in-
fection in transplant recipients following resolution of
CMV infection and/or disease. Risk factors for recurrent
CMVamong study populations have not been adequately de-
fined. In particular, donor and recipient serostatus, organ
transplanted, choice of immunosuppression, rejection and
its treatment, initial prophylactic strategies, the presence of
renal insufficiency, severity of disease, and the presence of
immune reconstitution have varied in those individuals
experiencing recurrent infection.108,178,222-224 Notably, risk
factors for recurrent infection may differ from those associ-
ated with primary infection or disease.223,224 Retrospective
analyses conducted in diverse transplant populations have not
demonstrated a benefit to secondary prophylaxis.108,222,223
Recurrent DNAemia upon completion of treatment and/or
preemptive therapy occurs, particularly in high-risk trans-
plant patients,173,195 although viral load replication may be
slower and subsequent peak viral load significantly lower
than the initial episode,172 possibly due to an evolving im-
mune response. Although many transplant centers treat all
recurrent episodes of CMV DNAemia, irrespective of a rele-
vant threshold,173 some episodes of CMV DNAemia may
resolve spontaneously.195
Prevention During Treatment of Rejection
Prophylaxis may be preferred over preemptive therapy in
certain high-risk patients, including those who have received
recent antilymphocyte therapy, potent immunosuppression
including desensitization or ABO incompatible protocols (in-
cluding those on rituximab, bortezomib, eculizumab, and
plasmapheresis/immunoadsorption), and those with human
immunodeficiency virus (HIV) (weak,moderate).225 Although
a retrospective cohort study (2007-2012) found no significant
difference in the incidence ofCMVinfection in patientswith or
without acute rejection (13% vs 10%, P = 0.37) 6 months af-
ter kidney transplant, the incidence of tissue-invasive CMV
disease (8% vs 3%, P = 0.04), particularly gastrointestinal
CMV disease, was significantly greater in patients with acute
rejection.226 In a retrospective cohort of 15848 adult kidney
transplant recipients between 2004 and 2010, early-onset
CMV disease was identified in 1.2% and delayed-onset
CMV disease in 4.0% of the kidney transplant recipients;
risk factors for delayed-onset CMV disease included trans-
plant failure or rejection (HR 3.2).227
Prevention During Critical Illness
Critical illness (includingmechanical ventilation and septic
shock) conveys an increased risk of CMV infection in
nontransplant patients, with associated increased mortal-
ity.228,229 The duration of acute illness (not severity) plays a
role inCMVreactivation.230 A randomized trial of GCVpro-
phylaxis in CMV-seropositive adults with critical illness due
to sepsis or trauma did not support its routine clinical use
in that population.231 Another trial in a critical illness popu-
lation found that valacyclovir or low-dose VGCV pro-
phylaxis suppressed CMV reactivation, but demonstrated
higher mortality in the valacyclovir arm.232 Transplant clini-
cians should be aware of the increased risk of CMV infection
with critical illness in normal hosts, as there may be a similar
effect in transplant recipients; however at this time there is in-
sufficient data to support routine use of antiviral prophylaxis
or enhanced monitoring in critically ill transplant recipients.
Lower-dose VGCV
Some centers, in hopes of improving tolerability and re-
ducing costs, employ half the recommended dose of VGCV
for prophylaxis (ie, 450 mg daily in patients with normal
renal function, sometimes called “mini-dosing.”233 This is
based on pharmacokinetic data showing comparable GCV
exposure with VGCV 450 mg and oral GCV 3 g daily.234,235
Published comparisons of low-dose versus standard-dose
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VGCV are limited to retrospective observational studies in
kidney transplant recipients.236-238 These studies suggest sim-
ilar CMV outcomes in intermediate risk patients (D+R+);
however, data are less clear in D+R− who are at higher risk
for breakthrough disease and development of resistance.236
Whether reduced VGCVexposure was achieved in any of these
studies is unclear because compliance with renal dosing proto-
cols cannot be assumed, and immunosuppressionmay not have
been standardized. There are no comparative studies of low
versus standard-dose VGCVin nonrenal transplant recipients.
CMV Immune Globulin
Cytomegalovirus immune globulin was first licensed for
use in prevention of primary CMVdisease in renal transplant
recipients.239,240 Its role in prophylaxis has been limited in
the era of antivirals, primarily due to limited effectiveness as
a single agent compared toGCVor VGCV, as well as expense
and infusion related toxicity (weak, moderate). It may be use-
ful for prevention in combination with antivirals in higher
risk (CMVD+/R−) lung or small bowel transplant recipients,
based on data in cohorts compared to historical controls
(weak, low).206,241,242 The combination demonstrated re-
duced incidence of CMVdisease, and bronchiolitis obliterans
syndrome (chronic rejection), with improved survival in a co-
hort of lung transplant recipients (weak, low).243 Use of the
combination has been based, in part, on the demonstration
of synergy between antibody (serum) and GCV in animal
models of lethal CMV infection.244 Adequately powered,
randomized trials measuring the additive benefit have not
yet been performed. Cytomegalovirus immune globulin has
no role for CMV prophylaxis in lung transplant recipients
when given alone. Cytomegalovirus immune globulin has
been used in patients for prophylaxis with prolonged
neutropenia who are intolerant of GCV. It has also been used
in patients with refractory CMV disease and hypogamma-
globinemia.101 In summary, CMV Ig is not generally recom-
mended for use, although there may be specific circumstances,
especially in thoracic organs, when used in combination with
antivirals, in which some benefit has been demonstrated.
There may be subtle in vitro differences between selected
immune globulin products with respect to titers of CMVan-
tibody but clinical differences have never been evaluated or
demonstrated. In vitro studies show consistently enhanced
functional antibody against CMV compared to regular intra-
venous immune globulin.245,246 Monoclonal antibodies are
in development and show potential promise for reduction
of CMV DNAemia and disease.247,248
Role of mTOR Inhibitors
Two systematic reviews and meta-analyses showed that
the incidence of CMV infection/disease is lower among pa-
tients receiving immunosuppressive regimens containing
mTOR inhibitors, suggesting that less prevention may be
needed in such patient.249,250 These findings are consistent
in kidney (high, strong),251,252 and in liver,253 heart,254-256
lung,257-259 and pediatric kidney transplant recipients260
(all moderate, strong).261 For example, in a single-center,
prospective study, among 288 patients randomized to receive
1 of 3 immunosuppression regimens, the lowest incidence of
CMV infection and disease was observed in patients who re-
ceived either of 2 everolimus-based regimens, with a propor-
tional reduction in CMVof 90% and 75%.262
Consensus Statements and Recommendations
• We recommend either universal prophylaxis or preemptive
therapy for prevention of CMVdisease (Table 6) (strong, high).
TABLE 6.
Recommended approaches for CMV prevention in different organs for adult SOTR
Organ Serostatus Risk level Recommended Alternate
All D−/R− Low Monitoring for clinical symptoms; consider
antiviral prophylaxis against other herpes infections
Preemptive therapy (if higher risk, ie,
significant transfusions)
Kidney D+/R− High 6 months of GCV/VGCV OR Preemptive therapy
R+ Intermediate 3 months of VGCV OR Preemptive therapy
Liver D+R− High 3 -6 months of VGCV (VGCV not FDA approved in liver)
OR Preemptive therapy
R+ Intermediate 3 months of VGCV (VGCV not FDA approved in liver)
OR Preemptive therapy
Pancreas D+R− High 3 -6 months of VGCV Preemptive therapy
R+ Intermediate 3 months of VGCV OR Preemptive therapy
Islet D+R− Intermediate 3 months of VGCV Preemptive therapy
R+ Intermediate 3 months of VGCV OR Preemptive therapy
Heart D+/R− High 3-6 months of GCV/VGCV -Preemptive therapy
-Some experts add CMV Ig to prophylaxis
R+ Intermediate 3 months of GCV/VGCV OR Preemptive therapy
Lung D+/R− High 6-12 months of GCV/VGCV -Preemptive therapy
-Some experts add CMV Ig to prophylaxis
R+ Intermediate Minimum 6 months of GCV/VGCV
Intestinal, composite
tissue
D+/R− High Minimum 6 months GCV/VGCV + − surveillance
after prophylaxis
-Preemptive therapy
-Some experts add CMV Ig
R+ High 3-6 months GCV/VGCV + − surveillance
after prophylaxis
When a range is given, the duration of prophylaxis may depend on degree of immunosuppression, including the use of antilymphocyte antibodies for induction.
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• For D+/R−, we recommend the use of either prophylaxis or
preemptive therapy after kidney and liver transplant (strong,
high). For programs or patients unable to meet the stringent
logistic requirements required with a preemptive therapy
strategy, prophylaxis is preferred.
• ForD+/R−, we suggest the use of prophylaxis over preemptive
therapy after heart and lung transplant, based on the available
data suggesting better graft survival and clinical outcomes
(weak, low). Preemptive therapy has not been well studied in
pancreas, islet, intestinal, and vascularized composite allo-
transplantation (ie, hand, face) such that prophylaxis may be
preferable over preemptive therapy until more data are avail-
able (weak, very low).
• For seropositive recipients (R+) after kidney or liver trans-
plant, we recommend either strategy (strong, high). Preemp-
tive therapy has not been well studied in some seropositive
populations including lung, heart, vascularized composite,
pancreas, islet, and intestinal transplant; we suggest prophy-
laxis may be preferable (weak, low).
• We suggest prophylaxis may be preferred in donor and/or re-
cipient seropositive patients whose risk for CMV may be in-
creased, including those on recent antilymphocyte therapy,
potent immunosuppression including desensitization or ABO in-
compatible protocols (including those on rituximab, bortezomib,
eculizumab, and plasmapheresis/immunoadsorption), and those
with HIV; a longer duration of prophylaxis (ie, 6 months)
may be more effective (weak, moderate).
• The choice of CMV prevention method should be determined
by the individual center, based on CMV disease incidence, im-
munosuppression, logistics of CMV surveillance, and eco-
nomic aspects.
• We recommend against routinelymonitoring patients for CMV
DNAemia while they are receiving standard-dose prophylactic
therapy based on renal function (Table 7) (strong, moderate).
• Use of surveillance after prophylaxis may be considered in pa-
tients considered at increased risk for postprophylaxis CMV
disease (weak, low). The value is probably greatest if done
weekly for 8 to 12 weeks. Biweekly or monthly monitoring
is insufficient for preemptive interventions (low, weak).
• With preemptive therapy, we recommend monitoring at least
once weekly for 3 to 4 months after transplant; longer moni-
toring would be indicated if they are perceived to be at ongo-
ing increased risk for CMV disease (strong, moderate).
• Programs should develop their own thresholds for initiating
treatment in preemptive therapy; this value may be different
for various populations.
• Once DNAemia is at a positive threshold, for asymptomatic
patients, we recommend VGCV (treatment dose) be started
[strong, high] and continued until resolution of DNAemia
(as per the Diagnostic section), with a minimum of 2 weeks
of treatment. After resolution, discontinue antiviral and con-
tinue weekly surveillance. Intravenous GCV is a less preferred
option unless concerns about absorption exist.
• If symptomatic, see Treatment section of these guidelines.
Prophylaxis Strategy D+/R−: Recommended Durations
• For D+/R− kidney recipients, prophylaxis for 6 months is
preferable (strong, high).
• In D+/R− liver, heart, and pancreas recipients, prophylaxis
should be 3months (strong, moderate) to 6 months (strong, low).
• For D+/R− islet recipients, prophylaxis for 3 months is recom-
mended (weak, low).
• Between 6 and 12 months prophylaxis is recommended for D
+/R− lung transplant recipients (strong, moderate).
• A minimum of 6 months of prophylaxis is recommended for
D+/R− vascularized composite (ie, hand and face) and intesti-
nal transplant recipients (weak, low).
TABLE 7.
Dosage recommendations for ganciclovir and valganciclovir and valacyclovir for adult patients with impaired renal function
(using Cockcroft-Gault formula)
Intravenous ganciclovir (adapted from265)
CrCl, mL/min Treatment dose Maintenance/prevention dose
≥70 5.0 mg/kg q12 h 5.0 mg/kg q24 h
50-69 2.5 mg/kg q12 h 2.5 mg/kg q24 h
25-49 2.5 mg/kg q24 h 1.25 mg/kg q24 h
10-24 1.25 mg/kg q24 h 0.625 mg/kg q24 h
<10 1.25 mg/kg 3 times a week after hemodialysis 0.625 mg/kg 3 times a week after hemodialysis
Valganciclovir (adapted from263,264)
CrCl, mL/min Treatment dose Maintenance/prevention dose
≥60 900 mg every 12 h 900 mg once daily
40-59 450 mg every 12 h 450 mg once daily
25-39 450 mg once daily 450 mg every 2 d
10-24 450 mg every 2 d 450 mg twice weekly
<10 200 mg 3 times a week after hemodialysisa 100 mg 3 times a week after hemodialysisa
Valacyclovir (high dose)167
CrCr, mL/min Prevention dose (kidney only)
>75 2000 mg 4 times per day
51-75 1500 mg 4 times per day
26-50 1500 mg 3 times per day
10-25 1500 mg twice daily
<10 or dialysis 1500 mg once daily
a Oral solution must be used in this instance (as VGCV tablets cannot be split).
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• When a range is given, the duration of prophylaxis may de-
pend on degree of immunosuppression, including the use of
antilymphocyte antibodies for induction.
Prophylaxis Strategy R+: Recommended Durations
• When a prophylaxis strategy is used for prevention in R+ pa-
tients (with either D+ or D−), a majority of the experts felt that
3 months of antiviral medication should be used for routine
kidney, pancreas, liver, and heart transplant recipients (strong,
high/moderate) and islet (weak, low).
• For those receiving more potent immunosuppression (antil-
ymphocyte antibody therapy, desensitization protocols) or
vascularized composite and intestinal transplant recipients,
between 3 and 6 months of prophylaxis can be used
(weak, low).
• In R+ lung transplant recipients, a minimum of 6 months pro-
phylaxis is recommended (strong, moderate).
Additional Consensus Recommendations in Prevention
• In CMV D−/R−, antiviral prophylaxis against other herpes
infections (varicella and herpes simplex) with acyclovir,
famciclovir, or valacyclovir should be considered (strong, high).
• To avoid transfusion-transmitted CMV, we recommend the
use of leukoreduced or CMV-seronegative blood products
(strong, moderate) especially in the highest risk group, D−/R−.
• Given the potential toxicity and cost, we do not recommend
the routine use of secondary prophylaxis after treatment of
CMV infection or disease (low, weak). We would consider ei-
ther secondary prophylaxis or preemptive therapy in certain
higher risk situations, that is, potent immunosuppression,
augmented risk of complications from recurrent CMV, or in-
ability to monitor closely due to extenuating circumstances
(weak, low).
• Local practices should guide management of recurrent epi-
sodes of DNAemia or utilization of relevant thresholds to ini-
tiate therapy given that there is insufficient evidence for an
optimal or cutoff or threshold (weak, low).
• We recommend that treatment of rejection with anti-
lymphocyte antibodies in at-risk recipients should result in
reinitiation of prophylaxis or preemptive therapy for 1 to
3 months (weak, moderate)266-268; a similar strategy may be
considered during treatment of rejection with high dose ste-
roids or plasmapharesis (weak, very low).
• CMV Ig is not generally recommended for use, although there
may be specific circumstances, especially in thoracic organs,
when used in combination with antivirals, some benefit has
been demonstrated (weak, low).
• We do not recommend the routine use of low-dose VGCV
(weak, low).
• CMV seropositive recipients receiving mTOR inhibitors have
a significantly lower incidence of CMV infection/disease. We
suggest the use of mTOR inhibitors as a potential approach
to decrease CMV infection and disease in CMV seropositive
kidney transplant recipients (high/strong) and in liver, heart,
and lung transplant recipients (moderate/strong). Cytomega-
lovirus risk is only one of the factors to consider when decid-
ing on the optimal immunosuppression regimen. The impact
of mTOR inhibitors on CMV in D+R− recipients is less clear.
Future Directions
• Despite many centers successfully deploying preemptive ther-
apy strategies, no clear universal thresholds have been de-
fined. In the absence of natural history studies, these may be
difficult to define in the current era.
• Future studies should assess potential ways to improve the ef-
ficacy of the surveillance after prophylaxis strategy such as
more stringent monitoring, optimal thresholds for initiating
antiviral therapy, use of viral kinetics, and the adjunctive use
of immunodiagnostic assays.
• Studies investigating the incidence of opportunistic infections,
including CMV, after treatment of acute rejection are needed.
While the majority of early acute rejection episodes occur dur-
ing the period of CMV prevention, a growing number of pa-
tients diagnosed with late acute rejection (cellular, antibody
mediated ormixed rejection) treated with various effective im-
munosuppressive strategies (thymoglobulin, rituximab, plas-
mapheresis, bortezomib, eculizumab) requires reevaluation
of CMV prevention strategies.
• We await more data on the use of novel antiviral agents for
CMV prevention, including maribavir, letermovir, and brincidofovir.
• Pathogen inactivation techniques may further reduce the risk
of transfusion-related CMV transmission.
• More data are needed in nonkidney solid organ transplant
and in high risk (D+/R−) recipients, both on the incidence of
primary and reactivation CMV episodes and on the efficacy
and safety of conversion to mTOR inhibitors after the first ep-
isode of CMV infection and disease. A large independent con-
firmatory trial is underway in kidney transplant recipients
(TRANSFORM trial).
CMV TREATMENT
Initial Treatment
Oral VGCV and intravenous GCV treatment are associ-
ated with similar long-term outcomes in SOTRs with CMV
syndrome and tissue-invasive CMV disease based on the
VICTOR study conducted in adult renal, liver, heart, and
lung transplant recipients.178 Although both may be used
for non–life-threatening CMV disease, VGCV is preferred
when feasible due to its oral formulation which may prevent
or reduce hospital stays and minimize the infectious and vas-
cular complications associated with intravenous therapy.
However, intravenous GCV is preferred as initial treatment
of life-threatening CMVdisease when optimal drug exposure
is essential. Furthermore, there are limited pharmacokinetic
data to confirm adequate VGCV bioavailability in patients
with gastrointestinal CMV disease.
Management
Appropriate antiviral dosing is essential in the manage-
ment of CMV disease (Table 7). Suboptimal dosing may
increase the risk for clinical treatment failure and the devel-
opment of resistance,269 whereas supratherapeutic doses
may increase toxicity.270 Renal function should be assessed
with regular monitoring of serum creatinine. Although the
PV16000166 and VICTOR271 trials used the Cockcroft-
Gault formula for (val)ganciclovir dosing, as does the pack-
age insert, other methods to estimate renal function are more
commonly used clinically (such as theModified Diet in Renal
Disease formula and Chronic Kidney Disease Epidemiology
Collaboration), and clinicians should be cognizant of this dif-
ference. Antiviral dose adjustment based on a population
pharmacokinetics Bayesian predictionmodelmay further op-
timize (val)ganciclovir exposure.272 In addition, complete
blood counts should also be monitored in regular intervals
to assess for hematologic toxicity (eg, leukopenia).
The intensity of immunosuppressive therapy can impact
the treatment outcomes associated with CMV disease.273,274
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Multiple studies include a reduction in immunosuppression
as a component of therapy. In addition, double (versus triple)
immunosuppressive therapy and lower blood concentrations
of calcineurin inhibitors are significantly associated with
eradication of CMV DNA at 21 days.273
Treatment Duration
CMV viral load should be monitored at weekly intervals
to guide the duration of therapy. Although whole blood is
more sensitive than plasma in detecting residual DNAemia,
it is not a better predictor of recurrent CMV disease.38 Fail-
ure to eradicate plasma DNAemia at the end of treatment is
the major significant predictor of virologic recurrence.178
Suppression of plasma CMV DNAemia measured with an
assay calibrated to the WHO predicts clinical response to
(val)ganciclovir.56 Reduction in antiviral dosing in the setting
of persistent CMV DNAemia at day 21 is associated with a
significant risk of GCV resistance by day 49.275 Therefore,
treatment doses of (val)ganciclovir are recommended until
eradication of CMV DNAemia below a specific threshold
and resolution of all clinical signs of CMV disease. Eradica-
tion of CMV DNAemia is defined as below LLOQ on 1
highly sensitive assay (LLOQ < 200 IU/mL; see Diagnostic
section), or lack of detection on 2 consecutive less sensitive
assays.With use of highly sensitive assays, a completely unde-
tectable viral load may not always be achievable. DNAemia
may not accurately reflect the clinical disease status in all situ-
ations. Therefore, longer courses of treatment may be needed
in the treatment of tissue-invasive gastrointestinal disease,
pneumonitis in lung transplant recipients, and central ner-
vous system or retinal disease. Secondary prophylaxis, de-
fined as continuing prophylactic doses after discontinuing
treatment dosing, is not associated with fewer relapses after
suppression of CMV DNA.60,108,222,275a
Consensus Statements and Recommendations
• For initial and recurrent episodes of CMV disease, VGCV
(900 mg every 12 hours) or intravenous GCV (5 mg/kg every
12 hours) are recommended as first-line treatment in adults
with normal kidney function (strong, moderate).
• Valganciclovir is recommended in patients with mild to mod-
erate CMV disease who can tolerate and adhere to oral med-
ication (strong, moderate).
• Intravenous GCV is recommended in life-threatening and se-
vere disease (strong, low).
• Oral GCV, acyclovir or valacyclovir are not recommended for
the treatment of CMV disease (strong, moderate).
• Adjunctive immunoglobulin therapy is not routinely recom-
mended (strong, low).
• In patients without concomitant rejection, reduction of immu-
nosuppression is suggested in the following settings: severe
CMV disease, inadequate clinical response, high viral loads,
and cytopenia (weak, very low).
• During the treatment phase, weekly plasma CMV DNA test-
ing is recommended using an assay calibrated to the WHO
standard to monitor response (strong, high).
• During the treatment phase, frequent monitoring of renal
function is recommended to guide dosage adjustments
(strong, moderate).
• Antiviral dosage reductions are only recommended during the
treatment phase to adjust for worsening renal function as sub-
optimal dosing may be associated with increased risk of clini-
cal failure and/or resistance (strong, low).
• In the setting of leukopenia, changing (val)ganciclovir to an-
other agent is not recommended before the addition of granu-
locyte colony stimulating factor and/or discontinuation of
other myelosuppressive therapies (strong, low).
• In patients who are intolerant to (val)ganciclovir during the
treatment phase, foscarnet (FOS) is the recommended second-
line agent (strong, very low).
• After clinical response, intravenous GCV may be transitioned
to VGCV in patients who are able to tolerate oral therapy
(strong, moderate).
• Due to individual variation in virologic response, change in
antiviral agent is not recommended in clinically improving pa-
tients with unchanged or rising DNAemia during the first few
weeks of therapy (strong, moderate).
• Drug resistance should be suspected in patients with a prior
cumulative (val)ganciclovir exposure that exceeds 6 weeks
and clinical treatment failure despite at least 2 weeks of antivi-
ral treatment or development of CMV DNAemia during pro-
phylaxis (see Resistance section)(strong, moderate).
• Antiviral treatment dosing should be continued for a mini-
mum of 2 weeks, until clinical resolution of disease and erad-
ication of CMV DNAemia below a specific threshold
(LLOQ < 200 IU/mL) on 1 or 2 consecutive weekly samples
(strong, moderate).
• Secondary prophylaxis is not routinely recommended
(low, weak).
Future Directions
Prospective studies in the following areas are needed
to evaluate novel strategies to optimize the treatment of
CMV disease:
• The application of CMV immune assays to guide duration
of treatment.
• The role for measuring and repleting immunoglobulins.
• The role for switching to an mTOR inhibitor.
• The role of therapeutic drug monitoring of GCV.
ANTIVIRAL DRUG RESISTANCE
Drug resistance is defined as a viral genetic alteration that
decreases susceptibility to 1 or more antiviral drugs. It may
manifest as a persistent or increasing viral load or symptom-
atic disease after a normally effective dosage and duration of
antiviral therapy. These clinical features do not in themselves
imply that drug resistance is present, but are used in the con-
text of relevant host factors to assess the need for diagnostic
testing and alternative therapy.
Risk Factors, Frequency, and Clinical Consequences
Risk factors for drug resistance include prolonged antiviral
drug exposure (median, 5 months for GCV) and ongoing ac-
tive viral replication due to factors such as the lack of prior
CMV immunity (D+/R−), strongly immunosuppressive ther-
apy, or inadequate antiviral drug delivery.276,277 Among
solid organ recipients the usual incidence of resistance after
GCV therapy is 5% to 12%,278-280 but up to 18% in
lung,275,281 and 31% in intestinal and multivisceral organ
transplant recipients.282,283 The incidence of resistance is
lower, in the 0% to 3% range, for 100 to 200 days of GCV
or VGCV prophylaxis in D+/R− kidney recipients.284 A
higher incidence of GCV resistance has sometimes been re-
ported with preemptive therapy as compared with prophy-
laxis where no viral load is expected at baseline.171,279 The
incidence of FOS and CDV resistance in transplant recipients
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is not well defined, but expected to be comparable to GCV
based on early studies in the AIDS setting.285 The relative in-
cidence of resistance to currently experimental drugs, such as
maribavir and letermovir, is unclear from the few case re-
ports so far.216,286,287 Drug-resistant CMV infection may
range from asymptomatic and resolving without treatment
change (eg, during antiviral prophylaxis284) to severe or fatal
end-organ disease.288 The development of drug resistance is
correlated with increased morbidity and mortality.277,289,290
Diagnosis of Drug Resistance
When to Test
Antiviral drug resistance should be suspected and tested
for when there is persistent or recurrent CMV DNAemia or
disease during prolonged antiviral therapy. For GCV, pro-
longed therapy generally means 6 or more weeks of cumula-
tive drug exposure, including longer than 2 weeks of ongoing
full dose therapy at the time of evaluation.277,278 With ad-
verse host factors and/or high starting viral loads, drug resis-
tance can occasionally be detected after less than 6 weeks of
drug exposure, as reported in several lung recipients.277 In a
large GCV and VGCV treatment trial,54 the viral load de-
clined with a median half-life of ~11 days after an initial lag
of ~6 days before any reduction was noted. The median time
to viral load below 200 copies/mL was 21 days; longer with
starting viral loads of more than 50000 copies/mL. Thus,
persistent viral loads in the first 2 weeks of treatment are
not predictive of emerging drug resistance,173,275 but failure
to achieve significant viral load reduction beyond this period
may reasonably be interpreted as an unsatisfactory response.
The kinetics of viral load response and risk for early emer-
gence of resistance may differ with newer antiviral drugs.
How to Test
Testing of CMV culture isolates for antiviral susceptibility
by reduction of plaque counts under increasing drug concen-
trations291 is technically impractical because of poor assay
standardization, slow turnaround and decreasing availability
of culture isolates. Instead, genotypic assays for viral drug re-
sistance mutations are performed on viral sequences directly
amplified from blood (whole blood, plasma or leukocytes),
fluids (urine, cerebrospinal, lung, eye), or tissue specimens.
The same blood specimens used for CMVQNATare usually
tested by amplification and sequencing of viral DNA. Results
are more reliable if the CMV copy number in the specimen is
at least 1000 IU/mL.292 Quality control concerns include
false positive detection of mutations, especially as mixed
populations from low viral load specimens,293 and false neg-
atives due to insensitivity in detecting mutant subpopulations
comprising less than 20% to 30% of the total.292,294 Evolv-
ing deep sequencing technologies offer the potential of detect-
ing far smaller mutant subpopulations.292,294-296 These early
reports have not yet established properly calibrated, ade-
quately sensitive, reproducible and stable technical platform
to serve as a base for clinical validation, including com-
parison with existing technology. There are reports of discor-
dant findings of resistance mutations at different body sites
(eye, cerebrospinal fluid).287,297,298 Indications of progres-
sive disease at tissue sites despite negative findings in blood
specimens may warrant the genotypic testing of tissue-
specific specimens.
Gene Regions to Test
These will evolve as new mutations are better characterized
and drug targets are developed. There is an increasing database
of CMV mutations associated with drug resistance.299-301
In patients initially treated with (val)ganciclovir, UL97 ki-
nase gene mutations appear first in about 90% of cases, af-
fecting drug phosphorylation that is necessary for antiviral
action.276-278,281 UL54 DNA polymerase gene mutations
usually evolve later, conferring increased GCV resistance
and likely cross-resistance to CDVand/or FOS, but may un-
commonly be the first mutation detected. Given increasing
availability, genotypic testing after GCV exposure should
now routinely include both the UL97 and UL54 genes. Ide-
ally, testing should cover the entire UL97 and UL54 coding
sequence, but many diagnostic laboratories test for more lim-
ited codon ranges, such as 450 to 650 for UL97, and 300 to
1000 for UL54, which cover the most common mutations
but omit some unusual loci where resistance mutations have
been reported (Figure 1, Table 8).
Interpretation of Genotypic Data
Test results are reported by diagnostic laboratories as a list
of mutations detected (sometimes as a mixture of mutant and
wild type sequences) and usually an indication of whether the
detected mutation confers resistance to particular drug(s).303
There is lack of standardization as to the level of drug resis-
tance conferred by the listed mutations, and whether reports
include sequence variants that are not in a list of resistance
mutations maintained by the laboratory.
Most UL97 mutations conferring GCV resistance are
strongly clustered at codons 460, 520, or 590 to 607, al-
though atypical loci exist.276,299,301 The 7 most common
(“canonical”) mutations (Table 8) account for over 80% of
cases. Other UL97 mutations may confer varying degrees of
GCV resistance (Table 8). UL97 mutations do not affect
FOS or CDV susceptibility. UL54 drug resistance mutations
tend to occur in the conserved functional domains and usu-
ally confer cross-resistance to other drugs (Figure 1), such
as the GCV-CDV dual resistance of exonuclease domain mu-
tations and the low-gradeGCV-FOS cross-resistance of DNA
polymerization (palm and finger) domain mutations. A few
single UL54mutations can confer resistance to all 3 drugs.276
Individual mutations are matched to their associated levels
of drug resistance by recombinant phenotyping, a research
technique whereby a mutation is transferred by recombina-
tion into a baseline laboratory strain (marker transfer) and
the resulting virus is tested against antiviral drugs (phenotyp-
ing) by a standardized assay calibrated to baseline and drug-
resistant control strains.276 The level of resistance is reported
as the change in the drug concentration that reduces viral
growth by 50% (EC50). For GCV, EC50 increases of two-
fold to fivefold may be considered low-grade, fivefold to
15-fold considered moderate (a level that may result from a
single UL97 mutation), and greater than 15-fold considered
a high level that suggests the combined effect of UL97 and
UL54 mutations. When both UL97 and UL54 mutations
are present, the combined level of GCVresistance may be ap-
proximated bymultiplying the fold changes in resistance con-
ferred by each mutation alone.304 Mutations that confer
slight decreases in susceptibility may significantly increase
the overall level of resistance when combined with other mu-
tations.305 Foscarnet resistance mutations typically confer
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twofold to fivefold increases in EC50 and frequently attenu-
ate viral growth.276 Some commonUL54 exonuclease domain
mutations confer 10- to 20-fold increases in CDV EC50.276
Uncharacterized sequence variants without a documented
phenotype cannot be presumed to be resistance-related with-
out careful analysis of such factors as sequencing quality
control, evolution in serial specimens, treatment history,
proximity to known gene mutations, and corroboration by
recombinant phenotyping.293
Alternate Therapy for Drug-resistant CMV
No controlled trial data define a best practice for selection
of alternate therapy when suspected or confirmed drug resis-
tance is present based on clinical risk factors or genotypic
testing. An updated algorithm (Figure 2) is based on consen-
sus expert opinion but its application to individual casesmust
take into account host factors that strongly influence out-
comes and the urgency of treatment changes. Depending on
the severity of the CMV disease (whether life or sight threat-
ening) and host risk factors (D+/R−, severe immunosuppres-
sion), empiric changes in therapy can be made when drug
resistance is suspected, pending return of genotypic resistance
data. Only a fraction of cases with clinical suspicion of drug
resistance will be genotypically confirmed.278 If laboratory
testing returns no evidence supporting drug resistance, em-
phasis should be given to optimization of host factors and
drug delivery rather than switching antiviral medications.
Therapeutic drug monitoring may be helpful in adjusting
doses to maintain effective drug levels in relation to viral in-
hibitory concentrations and minimize toxicity,306 although
timely availability of antiviral drug assays is limited. Subther-
apeutic GCV levels may increase the selection of resistant
mutants and risk of treatment failure.307-309 Additional geno-
typic testing over time, including specimens from diseased
body sites or use of validated deep sequencing technology
when available, may increase the sensitivity of detection of
FIGURE 1. CMV UL54 DNA polymerase gene mutation map. Shown are the structure domains and regions of amino acid sequence conser-
vation in herpesvirus polymerases, where resistance mutations are clustered. Corresponding resistance phenotypes are color coded for the
involved drugs. Adapted and updated from prior publications.5,276 BCV, brincidofovir; Nucs, various nucleoside analogs.
TABLE 8.
GCV resistance levels associated with selected UL97 genotypes
Fold change in GCV EC50a
Genotype frequency
5-15 2-5 <2
Most common M460V/I, H520Q, A594V, L595S, C603W C592G
Less common at codons
460, 590-607
M460T, A594G, 595delb, L595F/W, E596Y,
597del2b, 599del, K599T, 600del, 601del,
601del2, C603R, C607Y, del(≥3)c
A591V, A594E/T, E596G, C603S,
596delb, 600del2, C607F
E596D, N597D, K599E/R, L600I,
T601M, D605Ed
Atypical loci F342Se, K355Me,V356Ge, V466Ge, C480Re,
C518Y, P521Le
L405P, I610T, A613V M615V, Y617H, A619V, L634Q,
E655K, A674T
a Moderate resistance (5-15), low-grade resistance (2-5), or insignificant resistance (<2).
b del = in frame deletion of codon.
c In frame deletion of≥3 codons in the 590-607 range can be assumed to confer moderate GCV resistance (eightfold to 15-fold). Deletion of less than 3 codons may confer varying degrees of GCV resistance
(fourfold to 10-fold).302
d D605E is a baseline sequence polymorphism common in east Asia, unrelated to drug resistance.
e Maribavir cross-resistance documented; all except F342S are markedly growth-inhibited.
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resistance mutations. Immunosuppressive therapy should be
reduced to the lowest feasible amount, and adjunctive mea-
sures described in the next section can be considered.
Some UL97 mutations confer lower levels of GCV resis-
tance by themselves (Tables 8 and 272) and may be amenable
to GCV dose escalation (up to 10 mg/kg every 12 hours)
combined with optimization of host factors, if severe disease
is not present.310 This is double the standard dose and needs
monitoring for bone marrow suppression and dose adjust-
ment for renal function.
Switching to FOS is recommended if a mutation confers
higher level GCV resistance, or UL97 and UL54 mutations
combine to confer high level GCV resistance and usually
CDV cross-resistance. Foscarnet salvage therapy is often suc-
cessful at least initially,279,290 but metabolic and renal toxic-
ities may impair eventual treatment outcomes.311 There is
insufficient information on the efficacy of CDVas salvage ther-
apy in SOT.312,313 Nephrotoxicity is dose-limiting. Cidofovir
can be considered when GCVand FOS dual resistance is de-
tected without CDV resistance, but the rapid development of
viral load relapse and new CDV resistance mutations has
been repeatedly documented in case reports,287,294,314 prob-
ably related to undetected subpopulations of cross-resistant
mutants selected during prior GCV therapy.294 High-dose
GCV may also be an option for situations where FOS resis-
tance is present without associated high-level GCV resistance.
Adjunctive Therapy
Adjunctive treatments, defined as those without a specific
CMVantiviral drug target, have not been adequately evalu-
ated. Cytomegalovirus Ig (or IVIG) and adaptive infusions
of CMV-specific T cells146,315 may improve antiviral host de-
fenses. Several drugs used for other purposes, including
mTOR inhibitors (sirolimus and everolimus), leflunomide,
and artesunate, have anti-CMV effects in vitro that may
sometimes act synergistically with conventional antivirals.316,317
FIGURE 2. Proposed algorithm for management of suspected antiviral drug resistance, based on consensus expert opinion. There are no
controlled trials that define clinical outcomes according to genotypic diagnosis and selection of alternative therapy.
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Switching immunosuppressive therapy to an mTOR inhibi-
tor may be reasonable if otherwise tolerated, based on stud-
ies showing a lower incidence of CMV infection and
disease.318-320 Leflunomide has been advocated in case re-
ports and small series.321-324 Evidence for efficacy is limited
and caution is advised when used for cases of severe disease
or with high viral loads. Monitoring for drug metabolite
levels and liver toxicity is recommended. Use of artesunate
has been the subject of case reports,325,326withmixed outcomes
suggesting a similar degree of caution as with leflunomide.
Experimental CMV Antiviral Agents
Brincidofovir (CMX001) is an orally bioavailable deriva-
tive of CDV with improved intracellular active drug delivery
and in vitro antiviral potency. Although effective in a phase 2
trial as CMV prophylaxis in HSCT recipients,220 the follow-up
phase 3 trial failed primarily because of severe gastrointesti-
nal toxicity,327 and the drug is not currently available or be-
ing developed for CMV treatment. If eventuallymarketed for
some other indication, case reports of successful brincidofovir
salvage therapy328 may prompt further study. Resistance is
expected to involve similar UL54 mutations as CDV.329
Maribavir is an oral benzimidazole L-riboside inhibitor of
the CMV UL97 kinase.330 After promising early phase clini-
cal trials, phase 3 trials in HSCT and liver transplant recipi-
ents demonstrated no prophylactic efficacy of low-dose
(100 mg BID) maribavir.219,331 At higher doses, it has been
used as salvage therapy for drug resistant CMV infection,
with mixed results.332,333 A phase 2 trial of maribavir (400,
800, or 1200 mg bid) for salvage treatment of refractory
and resistant CMV infection has been completed, with indi-
cations of success in that approximately 67% achieved clear-
ance of DNAemia within 6 weeks, but infection recurred in
approximately 35%of thosewho cleared.334 Salvage efficacy
did not vary significantly among the 3 doses tried. Resistance
tomaribavir involves mutations in the UL97 kinase that con-
fer moderate to high level resistance, and assorted mutations
in the gene UL27 that confer low-level resistance.335 No
maribavir resistance was observed in the phase 3 prophylaxis
trials,335 but UL97 mutations T409M and H411Y/N appear
to be the most commonly detected after maribavir ther-
apy.286,287,333 These mutations confer approximately 80-fold
and approximately 12-fold increasedmaribavir EC50without
GCV cross-resistance. Although the UL97 mutations prefer-
entially elicited by GCV or maribavir do not confer cross-
resistance, there are atypical UL97mutations (Table 8), notably
the p-loop mutation F342S that confers GCVand maribavir
resistance without severely impairing viral growth fitness.336
Letermovir is a CMV UL56 terminase inhibitor with high
in vitro potency, which showed antiviral efficacy in placebo-
controlled phase 2 and phase 3 prophylaxis trials in HSCT
recipients.217,218 A case report suggests that letermovir sal-
vage therapy and reduced immunosuppression successfully
cleared a decreasing viral load after FOS therapy was limited
by toxicity,314 but the efficacy of letermovir in treating active
CMVinfection is unknown. A concern is that high-level resis-
tance to letermovir is readily elicited in vitro with little impact
on viral growth fitness, associated with mutations clustered
at codons 231 to 261, 325 and 369 of the UL56 gene.337,338
Mutations at codon 325 confer absolute resistance. No cross-
resistance with current antivirals is expected. Letermovir re-
sistance mutation UL56 V236M was encountered once in
each of the phase 2 and phase 3 prophylaxis trials,216,218
along with other mutations339; additional incidence data
are needed to enable comparison with the current DNA
polymerase inhibitors.
Consensus Statements and Recommendations
• Interpretation of genotypic resistance testing is based on
moderate- to high-quality evidence (depending on the muta-
tion and number of times tested) where recombinant pheno-
typing data are available, and low-quality evidence where a
phenotype is inferred from properties of mutations other than
the one being detected.
• We propose a management algorithm (Figure 2); given the
lack of controlled trial data to define a best practice for selec-
tion of alternate therapy when suspected or confirmed drug
resistance is present, the recommendations should be consid-
ered “strong, low” for the initial approach to diagnosis,
“moderate, low” for selection of alternate therapy, and “weak,
low” for CDVand other nonstandard salvage therapies.
Future Directions
• Prospective studies are needed to define the outcomes of drug-
resistant CMV under various management options.
• New therapeutic options are needed, with adequate potency,
bioavailability, and lack of toxicity and cross-resistance with
current drugs, including consideration of drug combinations
directed at different viral targets.
• Genotypic resistance testing needs improved quality control
and standardized reporting, including documentation of the
level of drug resistance and cross-resistance conferred by
various mutations.
• The role of next generation genotyping technology remains to
be defined.
PEDIATRIC ISSUES IN CMV MANAGEMENT
Prevention and treatment of CMV infection and disease
in pediatric and adolescent SOTRs present several unique
issues described here, incorporating and expanding on previ-
ous guidelines.4,5,340
Burden of CMV Disease in Pediatric SOT
There are limited data on the precise disease burden in pe-
diatric SOTRs. Nonuniform approaches to diagnosis, vary-
ing definitions of disease, and inconsistent durations of
monitoring hamper data interpretation. Epidemiological
studies conducted before the advent of prophylactic or pre-
emptive therapy indicated that as many as 40% of pediatric
liver and 15%of pediatric kidney transplant recipients devel-
oped CMV disease.341,342 With various antiviral prevention
strategies, CMV disease initially decreased to 10% to 20%
in pediatric liver transplant recipients343 with further declines
to 0% to 10% in more recent reports.344-349 Late-onset
CMV disease occurred in 6% of pediatric liver transplant re-
cipients. Declines in CMV disease from 24% to 12% also
have been documented in pediatric intestinal transplant re-
cipients after the introduction of antiviral prophylaxis.350,351
The incidence of CMV DNAemia after pediatric renal
transplantation is approximately 20%, with disease in
1-10%352–354 and late-onset disease in 14%.204 CMV was
detected in the blood in 29-32% of pediatric lung transplant
recipients in the first year, with CMV pneumonitis in 20%.
Late-onset CMV data has not been reported after pediatric
lung transplantation. DNAemia occurred in 38% of a small
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cohort of pediatric heart transplant recipients, with 8-9%
developing CMV disease in the Pediatric Heart Transplant
Study cohort over the first 5 years posttransplant.355,356
Primary Risk Factors for the Development of CMV
Disease in Children
As with adults, the risk of CMV disease in pediatric trans-
plant recipients varies with donor and recipient serostatus.
Interpretation of donor and recipient serostatus for infants
less than 12 months of age is confounded by the potential
presence of transplacentally-acquired maternal CMV anti-
bodies, and by the fact that CMV shedding in saliva or
urine among infected infants is intermittent. It is known
that CMV DNAemia may occur before transplantation in
infants with perinatal or postnatally acquired CMV infec-
tion, but it is not known if the presence of CMV DNAemia
before transplantation impacts the risk of CMV disease
posttransplantation.
Adult and pediatric patients share similar risk factors for
CMV disease after SOT, but there are a number of factors
that specifically influence the risk of CMV exposure and in-
fection among children. Children are more often CMV naïve
at the time of transplant and are therefore more likely to ac-
quire primary CMV infection post transplantation. CMV
D−/R− pediatric SOTRs are alsomore likely to acquire de novo
CMV infection from community exposures, such as daycare
attendance. As many as 7% of pediatric CMV D−/R− recip-
ients developed primary CMV infection in the first year
after transplantation.357
Indirect Effects of CMV in Pediatrics
The nature and definition of the indirect effects of CMV
may differ between children and adults. Studies performed
in the adult SOT population suggest significant indirect ef-
fects including increased risk of fungal and other opportunis-
tic infections, coronary artery vasculopathy and chronic
allograft rejection.358 Evidence does seem to support an asso-
ciation between CMV infection and long-term graft function
in pediatric kidney transplant recipients. Early studies in pe-
diatric kidney transplant recipients suggested an association
between CMV DNAemia and an increased risk of histologi-
cal graft rejection.353,359 One study was potentially con-
founded by the presence of EBV coinfection in half of the
small sample size.353 A recent multicenter cohort analysis in
pediatric renal transplant patients showed a significant asso-
ciation between CMV DNAemia and the decline of graft
function at 3 years posttransplant.354 Multivariate analysis
of variance investigating the impact of various factors on
eGFR revealed that, besides recipients' age at transplanta-
tion, CMV replication and acute rejection episodes were sig-
nificantly associated with a lower eGFR, whereas the type or
overall intensity of immunosuppressive therapy was not. The
use of antiviral prophylaxis in CMV D+/R− and D+/R+ pa-
tients was accompanied by a higher CMV-free survival and
a lower eGFR loss than preemptive therapy.354
Studies have not established a clear association between
CMV replication and negative outcomes in nonrenal pediat-
ric transplant recipients. In pediatric lung transplant recipi-
ents, CMV is associated with increased mortality within the
first year of transplantation,357 but an association with
chronic allograft rejection and opportunistic infections has
not been demonstrated.360,361 In heart transplantation, CMV
prophylaxis with either CMV Ig or antiviral agents was asso-
ciated with decreased mortality.362 Others have reported as-
sociation between CMV seropositivity and coronary artery
vasculopathy,363 but data from the multicenter Pediatric
Heart Transplant Study did not demonstrate this associa-
tion.356 In studies of pediatric liver transplant recipients,
CMV replication was not associated with immediate trans-
plant outcome, graft loss, death or with other potential
indirect CMV effects such as acute cellular rejection, sepsis,
EBV infection, biliary strictures and leakages or vascular
complications.344,345,348,364
In summary, available data suggest a significant negative
impact of CMV replication on pediatric renal graft function,
but this association has not been established in nonrenal pe-
diatric grafts. The lack of evidence linking CMV to substan-
tial indirect deleterious effects in nonrenal pediatric SOTRs,
coupled with the potential hematological toxicities associ-
ated with antiviral therapy in children,354,365,366 provide a
less compelling rationale for prolonged antiviral prophylaxis
or avoidance of preemptive therapy in most pediatric SOT.
Immunologic Monitoring in Pediatrics
The potential role of monitoring for general or CMV-
specific immune reconstitution has been explored only in un-
controlled and small studies in pediatric SOT.367 Children
under 2 years of age with both congenital and postnatal
CMV acquisition show decreased CMV-specific CD4 re-
sponses,368 although another study reported CMV-specific
responses in this cohort.21 Accordingly, it is clear that assays
assessing CMV cellular immunity must be validated across
the spectrum of ages in the pediatric population. Pediatric-
specific studies of T-cell responses and their potential role as bio-
markers of risk for CMV disease are needed before introducing
these assays into clinical practice (see Immunology section).
Prevention of Pediatric CMV Disease
As a first step in the prevention of CMV disease, the use of
leukodepleted or CMV-negative blood products is suggested
for special populations (eg, bowel, lung, and heart trans-
plants) and in CMV D−/R− patients. Prevention strategies
in pediatric SOTRs include antiviral prophylaxis, preemptive
therapy, or a sequential approach of brief prophylaxis
followed by viral load surveillance. Although no pediatric
trial has directly compared the relative efficacies of these 3
strategies, favorable outcomes for each have been reported
among pediatric SOTRs. There is broad collective evidence
to support the use of antiviral prophylaxis in pediatric recip-
ients, but its use in young children may be limited by bone
marrow suppression and limited VGCV pharmacokinetic
data. Conversely, preemptive therapy may avoid the toxic-
ities of antiviral exposure but requires intensive viral load
surveillance, and the threshold viral load to prompt antiviral
therapy is unknown. The rate of CMV disease has been re-
ported to be as low as 5% in relatively small studies of chil-
dren managed preemptively.369,370 The sequential approach
of a short course prophylaxis followed by viral load surveil-
lance, previously designated the “hybrid approach,” limits
the duration of prophylaxis to the period of most intense im-
munosuppression. This approach has been used successfully
in pediatric liver and heart transplant recipients, with re-
ported CMV disease rates of 8-10%.346,355 The reported du-
ration of prophylaxis in this setting typically ranges from 2 to
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4 weeks; however, the optimum duration of prophylaxis for
a sequential approach has not been defined.346,355,371
Prophylactic intravenous GCV is usually dosed at 5 mg/kg
per day. Some centers start with an initial dose of 10 mg/kg
in 2 divided doses based on the rationale that a higher (treat-
ment) dosemay reduce viral replicationwithin the graft,346,371
but no data support superiority of this approach. In contrast
to adults, the standard duration of prophylaxis varies sig-
nificantly between individual centers and among different
organs. In addition to reversible bone marrow toxicity, con-
cerns for prolonged exposure to GCVor VGCV in the very
young recipient have been raised due to animal toxicity stud-
ies demonstrating carcinogenesis or an adverse effect on sper-
matogenesis.372 These effects have not been observed in
humans, and prolonged IV GCV (12 weeks) has been used
safely in pediatric transplant recipients.373
Compared with adults, less data are available to define the
role of VGCV in pediatric SOTRs. Studies have addressed
pharmacokinetics (PK) in older children,374,375 and emerging
data address PK in younger SOT populations, including
infants. Current models support body surface area-based
dosing to reach targeted GCV AUC as opposed to weight-
based dosing.366,376-379 Data evaluating the efficacy of
VGCV for the prevention and treatment of CMV in pediatric
SOTRs are needed, particularly given concerns for lower
than anticipated plasma (and presumably intracellular) GCV
levels and the potential subsequent risk for GCV resistance.
Absorption issues might be of particular concern in small-
bowel transplant recipients. The efficacy and safety of
prolonged VGCV prophylaxis has not been the subject of
randomized studies in children.
The choice of immunosuppressive agent choice may im-
pact the risk for CMV disease. Subjects who received everoli-
mus with low-dose cyclosporine in a recent multicenter study
in pediatric kidney transplant recipients experienced a de-
creased risk of both CMV infection and disease compared
to standard therapy with cyclosporine or tacrolimus
with mycophenolate.260
Cytomegalovirus Ig and IVIG are sometimes used in com-
bination with antivirals or preemptive therapy to prevent
CMV. Data do not exist to enable a definitive recommenda-
tion for or against this practice. Evidence in support of this
strategy has been extrapolated from data derived mostly
from adult populations; however, some recent pediatric stud-
ies have been published with variable results.369,370,380,381 In
adult and pediatric heart transplant recipients, Scientific Reg-
istry of Transplant Recipients data showed an improvement
in recipient and graft survival for those who received CMV
Ig with or without antivirals; however, this improvement
was not different from that demonstrated with antivirals
alone.362,382 Krampe et al369 found a low incidence of
CMVdisease in 28 pediatric liver transplant recipients receiv-
ing IVIG and preemptive therapy but did not have a compar-
ison group. In a retrospective review of 329 pediatric lung
transplant recipients, of whom 62 (19%) received CMV Ig
in addition to at least 3 weeks of IV GCV, CMV Ig was asso-
ciated with a decreased risk of CMV infection but did not
impact the incidence of CMV disease, acute rejection or
early morbidity.380 A beneficial effect of CMV Ig on CMV
infection rates was also suggested by a combined pediatric
and adult study of intestinal/multivisceral transplant recipi-
ents.383 In 1 prospective randomized pediatric study that
primarily targeted EBV, CMV Ig did not appear to have a sig-
nificant impact on the development of CMV disease, al-
though there was a trend toward a higher 2-year CMV
disease-free rate in R+ children.343
Treatment of Pediatric CMV Disease
Many of the principles that guide therapy in children are
similar to those among adults. There is a significant lack of
published data on which to base firm recommendations for
the treatment of CMV disease in children, particularly re-
garding intravenous versus oral therapy. Valganciclovir has
been shown to be effective treatment of asymptomatic
CMVDNAemia in the setting of preemptive therapy, provid-
ing rationale for consideration of its use in mild to moderate
CMV disease.354
GCV Resistance in Pediatric Organ Transplantation
Due to the high likelihood of CMV D+/R− status in pedi-
atric SOTRs, GCV resistance is of significant potential con-
cern,384 although published reports from pediatric cohorts
report a low incidence of GCV resistance of only 2% to
4%.366,385,386 It is unclear if the reported incidence is due
to low resistance burden, lack of generated data, or under-
reporting. The currently available agents for the treatment
of GCV-resistant CMV in children are similar to those used
in adults.
Consensus Statements and Recommendations
• In general, the principles that guide the use of prophylaxis in
adults are similar in children as defined by the organ
transplanted and CMV donor and recipient serostatus.
• Significant updates from prior recommendations relate to
body surface area-based dosing for younger children and in-
fants and consideration for initial oral VGCV therapy for
CMV infection and mild to moderate CMV disease.
• Some experts perform surveillance during prophylaxis due to
concern for breakthrough DNAemia. If surveillance during
prophylaxis is performed, the frequency of surveillance should
take into account the immunosuppressive regimen (including
T cell–depleting induction) and the likelihood of nonadher-
ence with the prophylactic regimen. Adherence can be a par-
ticular problem with adolescents.
• Surveillance for CMV DNAemia among patients being man-
aged preemptively or with surveillance after prophylaxis regi-
mens should follow adult recommendations of weekly testing
and continue for at least 3 to 4 months posttransplant.
• Children with recurrent CMV DNAemia or disease (at least
2 episodes) may benefit from secondary antiviral prophylaxis.
The duration of secondary prophylaxis depends on immuno-
suppression regimen, age, presence of other opportunistic
infections, and other risk factors. Conversion to mTOR inhib-
itor based immunosuppression in pediatric kidney trans-
plant recipients may provide some protection against
recurrent CMV.
• Given the challenge of characterizing donor and recipient
serostatus in those less than 12 months of age (due to the pos-
sible presence of maternal antibodies), we recommend that
risk assessment in this age group should assume the highest
risk level for purposes of CMV prevention (strong, moderate)
(Table 9). It should be noted that the negative predictive value
of a culture or NAT is limited by intermittent CMV shedding.
• No pediatric trials have adequately evaluated the comparative
efficacy of prophylaxis, preemptive therapy or surveillance af-
ter prophylaxis strategies. Retrospective data provide equal
support for each these 3 prevention strategies, and as such
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all 3 are recommended (strong, moderate). The decision to
pursue specific strategies is dependent on organ type and risk
stratification (Table 10).
• Use of the VGCV-dosing algorithm that adjusts for body sur-
face area and renal function using the updated Schwartz for-
mula387 provides GCVexposures similar to those established
as safe and effective in adults and is recommended in infants
and children for prophylaxis (strong, moderate) (Table 11).
Recent data strongly supports body surface area (BSA)-based
dosing algorithm over the prior suggestion of 16 mg/kg
dosing for young infants (strong, moderate).
• The risk ofDNAemia is greatest during the 2 to 3months after
discontinuation of antiviral agents (for prevention or treat-
ment). Accordingly, we recommend recipients undergo fre-
quent monitoring for CMV DNAemia for at least this time
period (strong, moderate).
• For the treatment of asymptomatic DNAemia, we suggest the
use of oral VGCV (strong, low). In addition to patient age, an-
tiviral choice should be guided by early clinical assessment for
subtle CMV signs/symptoms, adherence, stable creatinine
clearance and oral absorption.
• We recommend the initial treatment of severe CMV disease in
children with IV GCV at a dose of 5 mg/kg every 12 hours
with appropriate adjustments for renal function (strong, mod-
erate). Some experts consider switching to oral therapy to-
wards the end of their treatment courses (strong, low). The
differential effectiveness of IV GCVor oral VGCV for the ini-
tial treatment of mild to moderate CMV disease in children
younger than 12 years has not been established. Treatment de-
cisions regarding delivery method should be individualized
based on age, adherence, and other modifying factors (weak,
very low).
• In the management of CMV infection and disease, immuno-
suppression should be reduced where feasible (strong, low).
• CMV Ig therapy is not routinely recommended for CMV dis-
ease (weak, low).
• In children at risk for CMV who receive significantly intensi-
fied immunosuppression (eg, antilymphocyte therapy, intrave-
nous steroids) for rejection, primary disease recurrence, or
other complicating condition, we recommend either prophy-
laxis with (val)ganciclovir or preemptive therapy (strong,
low). There are no data to suggest a specific duration of pro-
phylaxis in these circumstances.
Future Directions
• Reporting of the epidemiology and outcomes including CMV
infection and disease rates with current preventative strategies
and delineation of the short- and long-term indirect effects of
CMV in pediatric transplant recipients is encouraged. Such
reporting should be done using uniform criteria to enable
comparisons across studies.
• Additional investigation into the use of biomarkers to aid in
risk stratification for purposes of prevention and diagnosis
should be explored.
• Additional work is required on the utility of immunogenetic
biomarkers and adjunctive immunologic monitoring to guide
treatment strategies. Such work should consider age-related
immune maturity issues that might influence the optimal per-
formance of assays (eg, interferon gamma release assays).
• Investigation into optimal CMV prevention strategies should
include appreciation for the impact on different age groups
and the potential consequences of antiviral side effects in
pediatric-aged patients.
TABLE 9.
Assignment of donor/recipient serostatus in infants
< 12 months of age
Donor Recipient Highest risk categorization
+ + or − D+/R−a
− + D−/R+
− − D−/R−
aIf recipient confirmed positive by CMV culture or NAT, assign D+/R+.
TABLE 10.
Recommended regimens for CMV prevention in children
Organ Serostatusa Risk level Recommended Alternate
All except small
bowel
D−/R− Lowb Monitoring for clinical symptoms Preemptive therapy
Kidney R+ Intermediate 3-6 mo of VGCV as recommended in adultsc
OR Preemptive therapy
2-4 wk IV/PO with surveillance
after prophylaxisc
D+/R− High 3-6 mo of GCV/VGCV as recommended in adultsc
Liver D−/R+, D+/R+,
D+/R−
Intermediate
to high
2-4 wk of GCV/VGCV with surveillance after prophylaxisc
(VGCV not FDA approved in liver) OR 3-4 month of
VGCV OR Preemptive therapyc
Heart R+ Intermediate 2-4 wk GCV/VGCV with surveillance after prophylaxis
OR 3 months of GCV/VGCVc
D+/R− High 4 wk GCV/VGCV with surveillance after prophylaxis
OR3 months of GCV/VGCVc
Some experts add CMV Ig
Lung R+ High 6-12 mo of GCV/VGCV Shorter courses (3 mo) have been used
with surveillance after prophylaxis
D+/R− High 6-12 mo of GCV/VGCV Some experts add CMV Ig
Small boweld D−/R− Low Preemptive therapy OR 2 wk GCV with surveillance after prophylaxis
R+ High 2 wks GCV with surveillance after prophylaxis OR3-12 mo GCV/VGCV
D+/R− High 3-12 mo GCV/VGCV Some experts add CMV Ig
aRefer to serostatus recommendation for infants < 12 months of age.
bRisk of CMV infection in D−/R− is ~5-7% within 12 months of transplantation.
cT cell–depleting induction is associated with increased risk of CMV DNAemia and disease; consider prolonged prophylaxis or more intensive monitoring.
dVGCV should be used with extreme caution due to concerns for malabsorption in small bowel transplant recipients.
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• Pediatric data should be obtained for emerging antiviral
agents to expand the opportunities to prevent and treat CMV.
CONCLUSIONS
We have seen major advances in CMV management in
SOT (both adult and pediatric) over the past decade, with im-
proved molecular and immunologic diagnostics, reductions
in CMV infection and disease, better understanding of treat-
ment, and enhanced knowledge of treatment of resistant vi-
rus. Nonetheless, major gaps in our ability to provide
optimal care continue to exist, including viral load thresholds
to trigger antiviral therapy in asymptomatic individuals, best
use of immunodiagnostics and other methods to allow more
personalized approaches to CMV prevention and treatment,
ideal durations for prophylaxis in individual patients and
how to avoid the specter of late CMV, and determination of
best candidates for prophylaxis versus PET. Resistant CMV
remains challenging, with among the worst outcomes of all
patients afflicted by CMV infection. We look forward to
more advances, and to the day when we overcome the
“transplantation troll.”1
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